| Year |
Citation |
Score |
| 2024 |
Zhang X, Pant SM, Ritch CC, Tang HY, Shao H, Dweep H, Gong YY, Brooks R, Brafford P, Wolpaw AJ, Lee Y, Weeraratna A, Sehgal A, Herlyn M, Kossenkov A, et al. Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity. Nature Communications. 15: 633. PMID 38245503 DOI: 10.1038/s41467-024-44778-2 |
0.353 |
|
| 2023 |
Jagirdar K, Portuallo ME, Wei M, Wilhide M, Bravo Narula JA, Robertson BM, Alicea GM, Aguh C, Xiao M, Godok T, Fingerman D, Brown GS, Herlyn M, Elad VM, Guo X, et al. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma. Oncogene. PMID 38066089 DOI: 10.1038/s41388-023-02900-6 |
0.3 |
|
| 2023 |
Zhang W, Yang J, Wang B, Lu Y, Yang J, Zhong W, Yu Z, Qin Z, Xiao B, Wang K, Ma YY, Amaravadi R, Herlyn M, Kim J, Xu X, et al. HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. Cell Reports. 42: 113352. PMID 37948180 DOI: 10.1016/j.celrep.2023.113352 |
0.325 |
|
| 2023 |
Kim H, Feng Y, Murad R, Pozniak J, Pelz C, Chen Y, Dalal B, Sears R, Sergienko E, Jackson M, Ruppin E, Herlyn M, Harris C, Marine JC, Klepsch V, et al. Melanoma-intrinsic NR2F6 activity regulates antitumor immunity. Science Advances. 9: eadf6621. PMID 37406115 DOI: 10.1126/sciadv.adf6621 |
0.315 |
|
| 2023 |
Guo W, Zhong W, Xiao Z, Qin Z, Yang J, Wen Y, Yu Z, Li Y, Sheppard NC, Fuchs SY, Xu X, Herlyn M, June CH, Pure E. Tumor-derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. Cancer Research. PMID 37115855 DOI: 10.1158/0008-5472.CAN-22-2220 |
0.301 |
|
| 2022 |
Jain V, Harper SL, Versace AM, Fingerman D, Brown GS, Bhardwaj M, Crissey MAS, Goldman AR, Ruthel G, Liu Q, Zivkovic A, Stark H, Herlyn M, Gimotty PA, Speicher DW, et al. Targeting UGCG overcomes resistance to lysosomal autophagy inhibition. Cancer Discovery. PMID 36331284 DOI: 10.1158/2159-8290.CD-22-0535 |
0.304 |
|
| 2022 |
Ramirez-Salazar E, Herlyn M, Somasundaram R. Challenges in the humanized mouse model for cancer: A commentary. Journal of Cancer Biology. 2: 42-43. PMID 36283004 DOI: 10.46439/cancerbiology.2.022 |
0.316 |
|
| 2022 |
Stejerean-Todoran I, Zimmermann K, Gibhardt CS, Vultur A, Ickes C, Shannan B, Bonilla Del Rio Z, Wölling A, Cappello S, Sung HM, Shumanska M, Zhang X, Nanadikar M, Latif MU, Wittek A, ... ... Herlyn M, et al. MCU controls melanoma progression through a redox-controlled phenotype switch. Embo Reports. e54746. PMID 36156348 DOI: 10.15252/embr.202254746 |
0.337 |
|
| 2022 |
Chauvistré H, Shannan B, Daignault-Mill SM, Ju RJ, Picard D, Egetemaier S, Váraljai R, Gibhardt CS, Sechi A, Kaschani F, Keminer O, Stehbens SJ, Liu Q, Yin X, Jeyakumar K, ... ... Herlyn M, et al. Persister state-directed transitioning and vulnerability in melanoma. Nature Communications. 13: 3055. PMID 35650266 DOI: 10.1038/s41467-022-30641-9 |
0.334 |
|
| 2022 |
Dinavahi SS, Chen YC, Punnath K, Berg A, Herlyn M, Foroutan M, Huntington ND, Robertson GP. Targeting WEE1/AKT restores p53-dependent NK cell activation to induce immune checkpoint blockade responses in 'cold' melanoma. Cancer Immunology Research. PMID 35439317 DOI: 10.1158/2326-6066.CIR-21-0587 |
0.346 |
|
| 2022 |
Capparelli C, Purwin TJ, Glasheen M, Caksa S, Tiago M, Wilski N, Pomante D, Rosenbaum S, Nguyen MQ, Cai W, Franco-Barraza J, Zheng R, Kumar G, Chervoneva I, Shimada A, ... ... Herlyn M, et al. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nature Communications. 13: 1381. PMID 35296667 DOI: 10.1038/s41467-022-28801-y |
0.358 |
|
| 2022 |
Wei S, Yin D, Yu S, Lin X, Savani MR, Du K, Ku Y, Wu D, Li S, Liu H, Tian M, Chen Y, Bowie M, Hariharan S, Waitkus M, ... ... Herlyn M, et al. Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35247901 DOI: 10.1158/1078-0432.CCR-21-0833 |
0.501 |
|
| 2021 |
Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, ... ... Herlyn M, et al. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. Journal For Immunotherapy of Cancer. 9. PMID 34937742 DOI: 10.1136/jitc-2021-003339 |
0.477 |
|
| 2021 |
Hristova DM, Fukumoto T, Takemori C, Gao L, Hua X, Wang JX, Li L, Beqiri M, Watters A, Vultur A, Gimie Y, Rebecca V, Samarkina A, Jimbo H, Nishigori C, ... ... Herlyn M, et al. NUMB AS A NEW THERAPEUTIC TARGET FOR MELANOMA. The Journal of Investigative Dermatology. PMID 34883044 DOI: 10.1016/j.jid.2021.11.027 |
0.37 |
|
| 2021 |
Du K, Wei S, Wei Z, Frederick DT, Miao B, Moll T, Tian T, Sugarman E, Gabrilovich DI, Sullivan RJ, Liu L, Flaherty KT, Boland GM, Herlyn M, Zhang G. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nature Communications. 12: 6023. PMID 34654806 DOI: 10.1038/s41467-021-26299-4 |
0.495 |
|
| 2021 |
Min D, Byun J, Lee EJ, Khan AA, Liu C, Loudig O, Hu W, Zhao Y, Herlyn M, Tycko B, Cole PA, Ryu B. Epigenetic Silencing of BMP6 by the SIN3A-HDAC1/2 Repressor Complex Drives Melanoma Metastasis via FAM83G/PAWS1. Molecular Cancer Research : McR. PMID 34610961 DOI: 10.1158/1541-7786.MCR-21-0289 |
0.314 |
|
| 2021 |
Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, ... ... Herlyn M, et al. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34593527 DOI: 10.1158/1078-0432.CCR-21-0374 |
0.549 |
|
| 2021 |
de Oliveira ÉA, Chauhan J, da Silva JR, da Costa Carvalho LA, Dias D, de Carvalho DG, Watanabe LRM, Rebecca VW, Mills G, Lu Y, da Silva ASF, Consolaro MEL, Herlyn M, Possik PA, Goding CR, et al. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. Pharmacological Research. 105911. PMID 34560251 DOI: 10.1016/j.phrs.2021.105911 |
0.305 |
|
| 2021 |
Cappello S, Sung HM, Ickes C, Gibhardt CS, Vultur A, Bhat H, Hu Z, Brafford P, Denger A, Stejerean-Todoran I, Köhn RM, Lorenz V, Künzel N, Salinas G, Stanisz H, ... ... Herlyn M, et al. Protein signatures of NK cell-mediated melanoma killing predict response to immunotherapies. Cancer Research. PMID 34518212 DOI: 10.1158/0008-5472.CAN-21-0164 |
0.319 |
|
| 2021 |
Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, ... ... Herlyn M, et al. Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Research. PMID 34462276 DOI: 10.1158/0008-5472.CAN-20-1496 |
0.578 |
|
| 2021 |
Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, ... ... Herlyn M, et al. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. PMID 34304249 DOI: 10.1038/s41388-021-01911-5 |
0.558 |
|
| 2021 |
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, ... ... Herlyn M, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine. PMID 33941922 DOI: 10.1038/s41591-021-01331-8 |
0.546 |
|
| 2020 |
Marusak C, Thakur V, Li Y, Freitas JT, Zmina P, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, ... ... Herlyn M, et al. Targeting Extracellular Matrix Remodeling restores BRAF Inhibitor Sensitivity in BRAFi Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32820016 DOI: 10.1158/1078-0432.Ccr-19-2773 |
0.53 |
|
| 2020 |
Valiente M, Van Swearingen AED, Anders CK, Bairoch A, Boire A, Bos PD, Cittelly DM, Erez N, Ferraro GB, Fukumura D, Gril B, Herlyn M, Holmen SL, Jain RK, Joyce JA, et al. Brain Metastasis Cell Lines Panel: a public resource of organotropic cell lines. Cancer Research. PMID 32641416 DOI: 10.1158/0008-5472.Can-20-0291 |
0.328 |
|
| 2020 |
Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez-Gomez MJ, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan Hersh E, Livneh I, ... ... Herlyn M, et al. SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth. Molecular Cancer Research : McR. PMID 32571981 DOI: 10.1158/1541-7786.Mcr-20-0291 |
0.598 |
|
| 2020 |
Rebecca VW, Somasundaram R, Herlyn M. Pre-clinical modeling of cutaneous melanoma. Nature Communications. 11: 2858. PMID 32504051 DOI: 10.1038/S41467-020-15546-9 |
0.381 |
|
| 2020 |
Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, Webster MR, Kugel CH, Ecker BL, Caino MC, Kossenkov AV, Tang HY, Frederick DT, Flaherty KT, Xu X, ... ... Herlyn M, et al. Changes in Aged Fibroblast Lipid Metabolism Induce Age-dependent Melanoma Cell Resistance to Targeted Therapy Via the Fatty Acid Transporter FATP2. Cancer Discovery. PMID 32499221 DOI: 10.1158/2159-8290.Cd-20-0329 |
0.322 |
|
| 2020 |
Sharma S, Zhang T, Michowski W, Rebecca VW, Xiao M, Ferretti R, Suski JM, Bronson RT, Paulo JA, Frederick D, Fassl A, Boland GM, Geng Y, Lees JA, Medema RH, ... Herlyn M, et al. Targeting the cyclin-dependent kinase 5 in metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 32193336 DOI: 10.1073/Pnas.1912617117 |
0.427 |
|
| 2020 |
Liu W, Krump NA, Herlyn M, You J. Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity. Biology. 9. PMID 32093022 DOI: 10.3390/Biology9020035 |
0.416 |
|
| 2020 |
Lee J, Labrie M, Yong G, Camp T, Ma H, Grout M, Xu W, Beasley G, Schuchter LM, McGettigan S, O'Rourke DM, Herlyn M, Corless CL, Mills GB, Zhang G. Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies. Journal of Clinical Oncology. 38: e22015-e22015. DOI: 10.1200/Jco.2020.38.15_Suppl.E22015 |
0.614 |
|
| 2020 |
Atay C, Kwak T, Lavilla-Alonso S, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. Abstract B41: BRAF targeting sensitizes resistant melanoma to cytotoxic T cells Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-B41 |
0.638 |
|
| 2020 |
Woo XY, Giordano J, Srivastava A, Zhao Z, Lloyd MW, Bruijn Rd, Suh Y, Kim J, Yang H, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, ... ... Herlyn M, et al. Abstract 1673: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts Cancer Research. 80: 1673-1673. DOI: 10.1158/1538-7445.Am2020-1673 |
0.369 |
|
| 2019 |
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, ... ... Herlyn M, et al. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell. PMID 31836388 DOI: 10.1016/J.Molcel.2019.11.009 |
0.402 |
|
| 2019 |
Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A. MX2 is a novel regulator of cell cycle in melanoma cells. Pigment Cell & Melanoma Research. PMID 31660681 DOI: 10.1111/Pcmr.12837 |
0.462 |
|
| 2019 |
Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, Gagnon A, Judson RL, Ballotti R, Ribas A, Herlyn M, Rocchi S, Brown KM, Hayward NK, Yeh I, et al. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. Cell Reports. 29: 573-588.e7. PMID 31618628 DOI: 10.1016/J.Celrep.2019.09.009 |
0.36 |
|
| 2019 |
Seo JH, Chae YC, Kossenkov AV, Lee YG, Tang HY, Agarwal E, Gabrilovich DI, Languino LR, Speicher DW, Shastrula PK, Storaci AM, Ferrero S, Gaudioso G, Caroli M, Tosi D, ... ... Herlyn M, et al. MFF REGULATION OF MITOCHONDRIAL CELL DEATH IS A THERAPEUTIC TARGET IN CANCER. Cancer Research. PMID 31582380 DOI: 10.1158/0008-5472.Can-19-1982 |
0.345 |
|
| 2019 |
Zou Y, Watters A, Cheng N, Perry CE, Xu K, Alicea GM, Parris JLD, Baraban E, Ray P, Nayak A, Xu X, Herlyn M, Murphy ME, Weeraratna AT, Schug ZT, et al. Polyunsaturated Fatty Acids from Astrocytes Activate PPAR Gamma Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discovery. PMID 31578185 DOI: 10.1158/2159-8290.Cd-19-0270 |
0.306 |
|
| 2019 |
Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K, Maurer-Granofszky M, Roka F, Penz T, Bock C, Zhang G, Herlyn M, Glatz K, Läubli H, Mertz KD, et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications. 10: 4186. PMID 31519915 DOI: 10.1038/S41467-019-12160-2 |
0.607 |
|
| 2019 |
Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, ... ... Herlyn M, et al. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Reports. 28: 1971-1980.e8. PMID 31433975 DOI: 10.1016/J.Celrep.2019.07.084 |
0.534 |
|
| 2019 |
Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, ... ... Herlyn M, et al. A fatty acid oxidation-dependent metabolic shift regulates the adaptation of -mutated melanoma to MAPK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31375515 DOI: 10.1158/1078-0432.Ccr-19-0253 |
0.568 |
|
| 2019 |
Xiao M, Rebecca VW, Herlyn M. A Melanoma Patient-Derived Xenograft Model. Journal of Visualized Experiments : Jove. PMID 31157772 DOI: 10.3791/59508 |
0.437 |
|
| 2019 |
Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker BL, Yang R, Feltcher C, Peng K, Feng C, ... ... Herlyn M, et al. Author Correction: Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 10: 1211. PMID 30858377 DOI: 10.1038/S41467-019-09195-W |
0.448 |
|
| 2019 |
Sahu AD, S Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, ... ... Herlyn M, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology. 15: e8323. PMID 30858180 DOI: 10.15252/Msb.20188323 |
0.557 |
|
| 2019 |
Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, et al. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30765391 DOI: 10.1158/1078-0432.Ccr-18-2725 |
0.606 |
|
| 2019 |
Jerby L, Shah P, Cuoco MS, Rodman C, Su M, Melms JM, Leeson R, Kanodia A, Mei S, Lin J, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Herlyn M, et al. Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A082 |
0.616 |
|
| 2019 |
Das A, Lee JS, Zhang G, Wang Z, Amzallag A, Boland G, Hannenhalli S, Herlyn M, Benes C, Gutkind JS, Flaherty K, Ruppin E. Abstract LB-149: Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-149 |
0.579 |
|
| 2018 |
Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker B, Yang R, Feltcher C, Peng K, Feng C, ... ... Herlyn M, et al. Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 9: 5426. PMID 30575721 DOI: 10.1038/S41467-018-07126-9 |
0.598 |
|
| 2018 |
Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, ... ... Herlyn M, et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discovery. PMID 30563872 DOI: 10.1158/2159-8290.Cd-18-0348 |
0.576 |
|
| 2018 |
Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, ... ... Herlyn M, et al. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 30532003 DOI: 10.1038/S41586-018-0814-7 |
0.532 |
|
| 2018 |
Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, ... ... Herlyn M, et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discovery. PMID 30442709 DOI: 10.1158/2159-8290.Cd-18-0706 |
0.585 |
|
| 2018 |
Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Herlyn M, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 175: 984-997.e24. PMID 30388455 DOI: 10.1016/J.Cell.2018.09.006 |
0.616 |
|
| 2018 |
Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30333558 DOI: 10.1038/S41591-018-0247-8 |
0.482 |
|
| 2018 |
Kaur A, Ecker BL, Douglass SM, Kugel CH, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, ... ... Herlyn M, et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discovery. PMID 30279173 DOI: 10.1158/2159-8290.Cd-18-0193 |
0.36 |
|
| 2018 |
Pathria G, Scott DA, Feng Y, Sang Lee J, Fujita Y, Zhang G, Sahu AD, Ruppin E, Herlyn M, Osterman AL, Ronai ZA. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. The Embo Journal. PMID 30209241 DOI: 10.15252/Embj.201899735 |
0.592 |
|
| 2018 |
Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30127394 DOI: 10.1038/S41591-018-0157-9 |
0.537 |
|
| 2018 |
Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, ... ... Herlyn M, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. PMID 30089911 DOI: 10.1038/S41586-018-0392-8 |
0.501 |
|
| 2018 |
Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, ... ... Herlyn M, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine. PMID 30038220 DOI: 10.1038/S41591-018-0116-5 |
0.603 |
|
| 2018 |
Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, ... ... Herlyn M, et al. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29898988 DOI: 10.1158/1078-0432.Ccr-18-1116 |
0.304 |
|
| 2018 |
Zhou Y, Chen X, Kang B, She S, Zhang X, Chen C, Li W, Chen W, Dan S, Pan X, Liu X, He J, Zhao Q, Zhu C, Peng L, ... ... Herlyn M, et al. Endogenous authentic OCT4A proteins directly regulate FOS/AP-1 transcription in somatic cancer cells. Cell Death & Disease. 9: 585. PMID 29789579 DOI: 10.1038/S41419-018-0606-X |
0.378 |
|
| 2018 |
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, ... ... Herlyn M, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Embo Molecular Medicine. PMID 29650805 DOI: 10.15252/Emmm.201708446 |
0.595 |
|
| 2018 |
Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, ... ... Herlyn M, et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563139 DOI: 10.1158/1078-0432.Ccr-17-2773 |
0.573 |
|
| 2018 |
Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, ... ... Herlyn M, et al. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 9: 8206-8222. PMID 29492189 DOI: 10.18632/Oncotarget.23654 |
0.459 |
|
| 2018 |
Liu D, Zhang G, Shi A, Izar B, Heyde A, Kasumova GG, Frederick DT, Moll T, Sahu A, Ruppin E, Nowak M, Kellis M, Herlyn M, Lawrence DP, Flaherty K, et al. Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance. Journal of Clinical Oncology. 36: 9581-9581. DOI: 10.1200/Jco.2018.36.15_Suppl.9581 |
0.551 |
|
| 2018 |
Menon DR, Hammerlindl H, Emran AA, Torrano J, Hammerlindl S, Zhang G, Somasundaram R, Sturm RA, Haass NK, Flaherty K, Herlyn M, Schaider H. Abstract 5833: Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi resistant melanoma Cancer Research. 78: 5833-5833. DOI: 10.1158/1538-7445.Am2018-5833 |
0.595 |
|
| 2018 |
Menon DR, Hammerlindl H, Emran A, Torrano J, Hammerlindl S, Zhang G, Krause L, Somasundaram R, Sturm R, Haass NK, Flaherty K, Herlyn M, Schaider H. 1237 Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi-resistant melanoma Journal of Investigative Dermatology. 138. DOI: 10.1016/J.Jid.2018.03.1252 |
0.523 |
|
| 2017 |
Liu S, Tetzlaff MT, Wang T, Chen X, Yang R, Kumar SM, Vultur A, Li P, Martin JS, Herlyn M, Amaravadi R, Li B, Xu X. Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. Oncotarget. 8: 115140-115152. PMID 29383148 DOI: 10.18632/Oncotarget.22944 |
0.44 |
|
| 2017 |
Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, ... ... Herlyn M, et al. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Reports. 21: 2796-2812. PMID 29212027 DOI: 10.1016/J.Celrep.2017.11.022 |
0.38 |
|
| 2017 |
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, ... ... Herlyn M, et al. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports. 21: 1953-1967. PMID 29141225 DOI: 10.1016/J.Celrep.2017.10.021 |
0.55 |
|
| 2017 |
Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, ... ... Herlyn M, et al. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports. 21: 1936-1952. PMID 29141224 DOI: 10.1016/J.Celrep.2017.10.052 |
0.435 |
|
| 2017 |
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, ... ... Herlyn M, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. PMID 29101162 DOI: 10.1158/2159-8290.Cd-17-0833 |
0.571 |
|
| 2017 |
Harmeyer KM, Facompre ND, Herlyn M, Basu D. JARID1 Histone Demethylases: Emerging Targets in Cancer. Trends in Cancer. 3: 713-725. PMID 28958389 DOI: 10.1016/J.Trecan.2017.08.004 |
0.377 |
|
| 2017 |
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, ... ... Herlyn M, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 28953887 DOI: 10.1038/Nature24040 |
0.566 |
|
| 2017 |
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, ... ... Herlyn M, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications. 8: 607. PMID 28928360 DOI: 10.1038/S41467-017-00452-4 |
0.629 |
|
| 2017 |
Perego M, Maurer M, Wang JX, Shaffer S, Müller AC, Parapatics K, Li L, Hristova D, Shin S, Keeney F, Liu S, Xu X, Raj A, Jensen JK, Bennett KL, ... ... Herlyn M, et al. A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene. PMID 28925403 DOI: 10.1038/Onc.2017.341 |
0.423 |
|
| 2017 |
Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, ... ... Herlyn M, et al. A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer Discovery. PMID 28899863 DOI: 10.1158/2159-8290.Cd-17-0741 |
0.562 |
|
| 2017 |
Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, ... ... Herlyn M, et al. Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 32: 377-391.e9. PMID 28898698 DOI: 10.1016/J.Ccell.2017.08.004 |
0.559 |
|
| 2017 |
Ndoye A, Budina-Kolomets A, Kugel CH, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Vashisht Gopal YN, Davies MA, Mills GB, Xu X, Wu H, ... Herlyn M, et al. ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma. Cancer Research. PMID 28887323 DOI: 10.1158/0008-5472.Can-17-0907 |
0.403 |
|
| 2017 |
Noguchi S, Arakawa T, Fukuda S, Furuno M, Hasegawa A, Hori F, Ishikawa-Kato S, Kaida K, Kaiho A, Kanamori-Katayama M, Kawashima T, Kojima M, Kubosaki A, Manabe RI, Murata M, ... ... Herlyn M, et al. FANTOM5 CAGE profiles of human and mouse samples. Scientific Data. 4: 170112. PMID 28850106 DOI: 10.1038/Sdata.2017.112 |
0.309 |
|
| 2017 |
Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, ... Herlyn M, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. PMID 28607484 DOI: 10.1038/Nature22794 |
0.403 |
|
| 2017 |
Leu JI, Barnoud T, Zhang G, Tian T, Wei Z, Herlyn M, Murphy ME, George DL. Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function. Oncotarget. PMID 28484090 DOI: 10.18632/Oncotarget.17321 |
0.577 |
|
| 2017 |
Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, ... ... Herlyn M, et al. Oncogenic RAS regulates long non-coding RNA Orilnc1 in human cancer. Cancer Research. PMID 28473531 DOI: 10.1158/0008-5472.Can-16-1768 |
0.544 |
|
| 2017 |
Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, ... ... Herlyn M, et al. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 8: 25395-25417. PMID 28445987 DOI: 10.18632/Oncotarget.15915 |
0.516 |
|
| 2017 |
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. Jci Insight. 2: e89760. PMID 28097235 DOI: 10.1172/Jci.Insight.89760 |
0.392 |
|
| 2017 |
Tsao H, Fukunaga-Kalabis M, Herlyn M. Recent Advances in Melanoma and Melanocyte Biology. The Journal of Investigative Dermatology. PMID 28089201 DOI: 10.1016/J.Jid.2016.11.004 |
0.32 |
|
| 2017 |
Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. Abstract 1225: A unified model of RAF inhibitor action determines inhibitor activity in BRAF-dependent tumors Cancer Research. 77: 1225-1225. DOI: 10.1158/1538-7445.Am2017-1225 |
0.407 |
|
| 2017 |
George E, Kim H, Ragland R, Rafail S, Zhang R, Krepler C, Morgan MA, Herlyn M, Brown E, Simpkins F. Targeting the ATR-Chk1 axis with PARP inhibition results in tumor regression in BRCA mutant models Gynecologic Oncology. 145: 100. DOI: 10.1016/J.Ygyno.2017.03.236 |
0.344 |
|
| 2016 |
Herlyn M. 40 years in melanoma research: an interview with Meenhard Herlyn about his career in research and the outlook for the field. Melanoma Management. 3: 165-169. PMID 30190885 DOI: 10.2217/Mmt-2016-0015 |
0.442 |
|
| 2016 |
Somasundaram R, Herlyn M, Wagner SN. The role of tumor microenvironment in melanoma therapy resistance. Melanoma Management. 3: 23-32. PMID 30190870 DOI: 10.2217/Mmt.15.37 |
0.457 |
|
| 2016 |
Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27993965 DOI: 10.1158/1078-0432.Ccr-16-2273 |
0.381 |
|
| 2016 |
Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA. PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. Plos Genetics. 12: e1006518. PMID 27977682 DOI: 10.1371/Journal.Pgen.1006518 |
0.624 |
|
| 2016 |
Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Uribe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, ... ... Herlyn M, et al. Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget. PMID 27655717 DOI: 10.18632/Oncotarget.12078 |
0.394 |
|
| 2016 |
Wu LW, Zhang G, Herlyn M. Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma. Molecular & Cellular Oncology. 3: e1179381. PMID 27652325 DOI: 10.1080/23723556.2016.1179381 |
0.566 |
|
| 2016 |
Wang JX, Fukunaga-Kalabis M, Herlyn M. Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. Journal of Cell Communication and Signaling. PMID 27553358 DOI: 10.1007/S12079-016-0349-3 |
0.416 |
|
| 2016 |
Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. PMID 27523909 DOI: 10.1016/J.Ccell.2016.06.024 |
0.346 |
|
| 2016 |
Facompre ND, Harmeyer KM, Sole X, Kabraji S, Belden Z, Sahu V, Whelan K, Tanaka K, Weinstein GS, Montone KT, Roesch A, Gimotty PA, Herlyn M, Rustgi AK, Nakagawa H, et al. JARID1B enables transit between distinct states of the stem-like cell population in oral cancers. Cancer Research. PMID 27488530 DOI: 10.1158/0008-5472.Can-15-3377 |
0.392 |
|
| 2016 |
Shannan B, Watters A, Chen Q, Mollin S, Dörr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, ... ... Herlyn M, et al. PIM kinases as therapeutic targets against advanced melanoma. Oncotarget. PMID 27448973 DOI: 10.18632/Oncotarget.10703 |
0.622 |
|
| 2016 |
Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, Aird KM, Zhang R. Targeting RRM2 and Mutant BRAF is a Novel Combinatorial Strategy for Melanoma. Molecular Cancer Research : McR. PMID 27297629 DOI: 10.1158/1541-7786.Mcr-16-0099 |
0.426 |
|
| 2016 |
Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, ... ... Herlyn M, et al. Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports. PMID 27210749 DOI: 10.1016/J.Celrep.2016.04.073 |
0.61 |
|
| 2016 |
Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, et al. The state of melanoma: challenges and opportunities. Pigment Cell & Melanoma Research. PMID 27087480 DOI: 10.1111/Pcmr.12475 |
0.322 |
|
| 2016 |
Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, ... ... Herlyn M, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. The Journal of Clinical Investigation. PMID 27043285 DOI: 10.1172/Jci82661 |
0.584 |
|
| 2016 |
Vultur A, Schanstra T, Herlyn M. The promise of 3D skin and melanoma cell bioprinting. Melanoma Research. 26: 205-6. PMID 26925984 DOI: 10.1097/Cmr.0000000000000233 |
0.326 |
|
| 2016 |
Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, ... Herlyn M, et al. Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell & Melanoma Research. PMID 26850518 DOI: 10.1111/Pcmr.12465 |
0.35 |
|
| 2016 |
Bonyadi Rad E, Hammerlindl H, Wels C, Popper U, Ravindran Menon D, Breiteneder H, Kitzwoegerer M, Hafner C, Herlyn M, Bergler H, Schaider H. Notch4 signaling induces a mesenchymal-epithelial-like transition in melanoma cells to suppress malignant behaviors. Cancer Research. PMID 26801977 DOI: 10.1158/0008-5472.CAN-15-1722 |
0.324 |
|
| 2016 |
Shannan B, Perego M, Somasundaram R, Herlyn M. Heterogeneity in Melanoma. Cancer Treatment and Research. 167: 1-15. PMID 26601857 DOI: 10.1007/978-3-319-22539-5_1 |
0.334 |
|
| 2016 |
Brafford P, Sproesser K, Krepler C, Herlyn M. 1205Lu is Human Melanoma Depending on the Source Journal of Cancer Science & Therapy. 8: 0-0. DOI: 10.4172/1948-5956.1000401 |
0.36 |
|
| 2016 |
Wu LW, Zhang G, Herlyn M. Repurposing an HIV drug to improve efficacy of targeted therapy in melanoma Translational Cancer Research. 5. DOI: 10.21037/8186 |
0.599 |
|
| 2016 |
Krepler C, Perego M, Kalabis M, Beqiri M, Hristova D, Xiao M, Petrelli NJ, Somasundaram R, Herlyn M. Abstract PR02: Humanized mouse melanoma model using patient-derived xenografts Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-Pr02 |
0.436 |
|
| 2016 |
Krepler C, Sproesser K, Beqiri M, Xiao M, Brafford P, Xu W, Garman B, Wargo J, Davies MA, Frederick DT, Flaherty KT, Hoon D, Bennett JJ, Guarino M, Petrelli NJ, ... ... Herlyn M, et al. Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A01 |
0.392 |
|
| 2016 |
George E, Kim H, Krepler C, Tanyi J, Wei Z, Sproesser K, Brafford P, Beqiri M, Vultur A, Lee R, Morgan M, Drapkin R, Ince T, Herlyn M, Simpkins F. Abstract B46: Use of a novel orthotopic ovarian cancer transplant patient derived xenograft model as a preclinical platform for bench to bedside research. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B46 |
0.405 |
|
| 2016 |
Kim H, George E, Brown E, Zhang R, Krepler C, Tanyi J, Lee R, Morgan M, Herlyn M, Simpkins F. Abstract A08: Targeting the ATR/CHK1 axis in BRCA1/2 mutant ovarian cancer using an orthotopic patient-derived xenograft (PDX) model. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A08 |
0.371 |
|
| 2016 |
Shaffer SM, Biaesch AG, Torborg S, Krepler C, Herlyn M, Raj A. Abstract B32: Single-cell non-genetic heterogeneity confers drug resistance in melanoma Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-B32 |
0.384 |
|
| 2016 |
Emran AA, Menon DR, Soyer P, Gabrielli B, Sturm R, Herlyn M, Schaider H. Abstract B34: Global histone modifications define early stress induced drug tolerance in cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B34 |
0.327 |
|
| 2016 |
BonyadiRad E, Hammerlindl H, Menon DR, Hafner C, Herlyn M, Schaider H. Abstract 1679: Notch4 mediates mesenchymal-epithelial-like transition in melanoma Cancer Research. 76: 1679-1679. DOI: 10.1158/1538-7445.Am2016-1679 |
0.386 |
|
| 2016 |
Rebecca VW, Nicastri M, McGlaughlin N, McAfee Q, Zhang G, Alicea GM, Piao S, Fennelly C, Murugan S, Wei Z, Mills GB, Lu Y, Herlyn M, Winkler JD, Amaravadi RK. Abstract 1018: Structural features of novel dimeric quinacrines that have single-agent antitumor activity determine the mechanism of action: destabilization of mTORC1/lysosomal interaction versus DNA damage Cancer Research. 76: 1018-1018. DOI: 10.1158/1538-7445.Am2016-1018 |
0.514 |
|
| 2016 |
Hristova D, Hua X, Wang J, Li L, Beqiri M, Watters A, Vultur A, Wei Z, Herlyn M, Fukunaga-Kalabis M. 662 Numb is induced by GSK3 inhibition and inhibits melanoma migration, invasion and metastasis Journal of Investigative Dermatology. 136: S117. DOI: 10.1016/J.Jid.2016.02.703 |
0.318 |
|
| 2016 |
Fukunaga-Kalabis M, Heppt MV, Wang JX, Hristova DM, Wei Z, Irmler M, Berking C, Besch R, Beckers J, Rauscher FJ, Fisher DE, Herlyn M. MSX1 promotes melanoma progression via neural crest-like reprogramming Journal of Dermatological Science. 84. DOI: 10.1016/J.Jdermsci.2016.08.268 |
0.301 |
|
| 2015 |
Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Melanoma. Nature Reviews. Disease Primers. 1: 15003. PMID 27188223 DOI: 10.1038/nrdp.2015.3 |
0.313 |
|
| 2015 |
Swoboda RK, Somasundaram R, Caputo-Gross L, Marincola FM, Robbins P, Herlyn M, Herlyn D. Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. Molecular Therapy Oncolytics. 1: 14009. PMID 27119099 DOI: 10.1038/Mto.2014.9 |
0.337 |
|
| 2015 |
Li L, Fukunaga-Kalabis M, Herlyn M. Establishing Human Skin Grafts in Mice as Model for Melanoma Progression. Methods in Molecular Biology (Clifton, N.J.). PMID 26659798 DOI: 10.1007/7651_2015_301 |
0.402 |
|
| 2015 |
Wang T, Feldman GM, Herlyn M, Kaufman RE. The macrophage: Switches from a passenger to a driver during anticancer therapy. Oncoimmunology. 4: e1052929. PMID 26587324 DOI: 10.1080/2162402X.2015.1052929 |
0.341 |
|
| 2015 |
Wang YJ, Herlyn M. The emerging roles of Oct4 in tumor-initiating cells. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. American Journal of Physiology. Cell Physiology. ajpcell.00212.2015. PMID 26447206 DOI: 10.1152/Ajpcell.00212.2015 |
0.435 |
|
| 2015 |
Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Review of Anticancer Therapy. 15: 1135-41. PMID 26402246 DOI: 10.1586/14737140.2015.1093418 |
0.384 |
|
| 2015 |
McNeal AS, Liu K, Nakhate V, Natale CA, Duperret EK, Capell BC, Dentchev T, Berger SL, Herlyn M, Seykora JT, Ridky TW. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma. Cancer Discovery. 5: 1072-85. PMID 26183406 DOI: 10.1158/2159-8290.Cd-15-0196 |
0.401 |
|
| 2015 |
Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, et al. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports. 11: 1458-73. PMID 26027934 DOI: 10.1016/J.Celrep.2015.04.049 |
0.304 |
|
| 2015 |
Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, ... Herlyn M, et al. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell & Melanoma Research. 28: 431-41. PMID 25903073 DOI: 10.1111/Pcmr.12379 |
0.542 |
|
| 2015 |
Fukunaga-Kalabis M, Hristova DM, Wang JX, Li L, Heppt MV, Wei Z, Gyurdieva A, Webster MR, Oka M, Weeraratna AT, Herlyn M. UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch. The Journal of Investigative Dermatology. 135: 1521-32. PMID 25705850 DOI: 10.1038/Jid.2015.59 |
0.377 |
|
| 2015 |
Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, ... Herlyn M, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. PMID 25619837 DOI: 10.1038/Onc.2014.432 |
0.475 |
|
| 2015 |
Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, ... ... Herlyn M, et al. BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1652-64. PMID 25617424 DOI: 10.1158/1078-0432.Ccr-14-1554 |
0.586 |
|
| 2015 |
Slipicevic A, Herlyn M. KIT in melanoma: many shades of gray. The Journal of Investigative Dermatology. 135: 337-8. PMID 25573046 DOI: 10.1038/Jid.2014.417 |
0.373 |
|
| 2015 |
Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine B, Amaravadi RK, Speicher DW. Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy. 11: 60-74. PMID 25484078 DOI: 10.4161/15548627.2014.984273 |
0.598 |
|
| 2015 |
Cierlitza M, Chauvistré H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, Vogt T, Roesch A. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Experimental Dermatology. 24: 155-7. PMID 25453510 DOI: 10.1111/Exd.12613 |
0.392 |
|
| 2015 |
Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, ... ... Herlyn M, et al. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell & Melanoma Research. 28: 184-95. PMID 25407936 DOI: 10.1111/Pcmr.12330 |
0.586 |
|
| 2015 |
Webster MR, Xu M, Kinzler K, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang V, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, ... ... Herlyn M, et al. Abstract B27: Wnt5A-expressing melanoma cells show classical markers of senescence following radiation and therapeutic stress, but retain the ability to metastasize and proliferate at distant sites Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-B27 |
0.543 |
|
| 2015 |
Heppt MV, Joshua WX, Hristova DM, Wei Z, Irmler M, Berking C, Besch R, Beckers J, Rauscher FJ, Fisher DE, Herlyn M, Fukunaga-Kalabis M. Abstract A13: MSX1-induced neural crest-like reprograming promotes melanoma progression Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A13 |
0.373 |
|
| 2015 |
Vultur AM, Shannan B, Chen Q, Watters A, Mollin S, Meggers E, Krepler C, Perego M, Li L, Gimotty PA, Xu X, Herlyn M. Abstract 687: Compound screen identifies PIM kinases as therapeutic targets for melanoma Cancer Research. 75: 687-687. DOI: 10.1158/1538-7445.Am2015-687 |
0.414 |
|
| 2015 |
Somasundaram R, Zhang G, Wagner SN, Fukunaga-Kalabis M, Herlyn M. Abstract 420: The role of tumor microenvironment in therapy resistance and melanoma progression Cancer Research. 75: 420-420. DOI: 10.1158/1538-7445.Am2015-420 |
0.634 |
|
| 2015 |
Krepler C, Xiao M, Sproesser K, Brafford P, Shannan B, Beqiri M, Xu W, Garman B, Nathanson KL, Xu X, Karakousis G, Mills GB, Lu Y, Caponigro G, Boehm M, ... ... Herlyn M, et al. Abstract 2842: Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target Cancer Research. 75: 2842-2842. DOI: 10.1158/1538-7445.Am2015-2842 |
0.398 |
|
| 2015 |
Menon DR, Das S, Krepler C, Vultur A, Zhang G, Haass N, Soyer PH, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H. Abstract 2684: An early innate stress response precedes acquired drug resistance in melanoma Cancer Research. 75: 2684-2684. DOI: 10.1158/1538-7445.Am2015-2684 |
0.571 |
|
| 2015 |
Facompre N, Belden Z, Gimotty P, Rustgi A, Herlyn M, Nakagawa H, Basu D. Abstract 1517: G0-like cells support an oral cancer stem cell pool by transitioning to a JARID1B-high state Cancer Research. 75: 1517-1517. DOI: 10.1158/1538-7445.Am2015-1517 |
0.404 |
|
| 2015 |
Fukunaga-Kalabis M, Hristova D, Wang J, Li L, Heppt M, Wei Z, Gyurdieva A, Webster M, Oka M, Weeraratna A, Herlyn M. Abstract 1508: UV-induced Wnt7a in the human skin microenvironment specifies the fate of neural crest -like cells via suppression of Notch Cancer Research. 75: 1508-1508. DOI: 10.1158/1538-7445.Am2015-1508 |
0.342 |
|
| 2014 |
Yang R, Zheng Y, Li L, Liu S, Burrows M, Wei Z, Nace A, Herlyn M, Cui R, Guo W, Cotsarelis G, Xu X. Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors. Nature Communications. 5: 5807. PMID 25510211 DOI: 10.1038/Ncomms6807 |
0.357 |
|
| 2014 |
Ravindran Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Bonyadi Rad E, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, ... Herlyn M, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. PMID 25417704 DOI: 10.1038/Onc.2014.372 |
0.552 |
|
| 2014 |
Liu J, Fukunaga-Kalabis M, Li L, Herlyn M. Developmental pathways activated in melanocytes and melanoma. Archives of Biochemistry and Biophysics. 563: 13-21. PMID 25109840 DOI: 10.1016/J.Abb.2014.07.023 |
0.418 |
|
| 2014 |
Zhang G, Herlyn M. Linking SOX10 to a slow-growth resistance phenotype. Cell Research. 24: 906-7. PMID 24853952 DOI: 10.1038/Cr.2014.67 |
0.569 |
|
| 2014 |
Somasundaram R, Herlyn M. Indomethacin to the rescue of TRAIL-resistant melanomas. The Journal of Investigative Dermatology. 134: 1198-9. PMID 24732334 DOI: 10.1038/Jid.2014.1 |
0.356 |
|
| 2014 |
Forrest AR, Kawaji H, Rehli M, Baillie JK, de Hoon MJ, Haberle V, Lassmann T, Kulakovskiy IV, Lizio M, Itoh M, Andersson R, Mungall CJ, Meehan TF, Schmeier S, ... ... Herlyn M, et al. A promoter-level mammalian expression atlas. Nature. 507: 462-70. PMID 24670764 DOI: 10.1038/Nature13182 |
0.347 |
|
| 2014 |
Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, et al. LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Research. 74: 1390-403. PMID 24590809 DOI: 10.1158/0008-5472.Can-13-1275 |
0.302 |
|
| 2014 |
Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, ... ... Herlyn M, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. The Journal of Clinical Investigation. 124: 1406-17. PMID 24569374 DOI: 10.1172/Jci70454 |
0.595 |
|
| 2014 |
Geserick P, Herlyn M, Leverkus M. On the TRAIL to overcome BRAF-inhibitor resistance. The Journal of Investigative Dermatology. 134: 315-8. PMID 24424456 DOI: 10.1038/Jid.2013.348 |
0.367 |
|
| 2014 |
Slipicevic A, Somasundaram R, Sproesser K, Herlyn M. Isolation of melanoma cell subpopulations using negative selection. Methods in Molecular Biology (Clifton, N.J.). 1102: 501-12. PMID 24258995 DOI: 10.1007/978-1-62703-727-3_26 |
0.459 |
|
| 2014 |
Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, Vogt T, Xu X, Hwang WT, Lieu M, Belser E, Liu R, Somasundaram R, ... Herlyn M, et al. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. The Journal of Investigative Dermatology. 134: 1108-18. PMID 24157461 DOI: 10.1038/Jid.2013.437 |
0.389 |
|
| 2014 |
Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M, Mauviel A. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. The Journal of Investigative Dermatology. 134: 123-32. PMID 23897276 DOI: 10.1038/Jid.2013.319 |
0.452 |
|
| 2014 |
Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL, Herlyn M. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines Oncogene. 33: 1850-1861. PMID 23624919 DOI: 10.1038/Onc.2013.131 |
0.43 |
|
| 2014 |
Peng H, Farrooji MTZ, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, et al. Abstract 992: LIMD2 is a small LIM-only protein overexpressed in metastatic lesions which regulates cell motility and tumor progression by directly binding to and activating the integrin-linked-kinase Cancer Research. 74: 992-992. DOI: 10.1158/1538-7445.Am2014-992 |
0.441 |
|
| 2014 |
Krepler C, Sproesser K, Brafford P, Xiao M, Beqiri M, Xu W, Nathanson K, Wargo J, Flaherty K, Morton DL, Hoon DS, Ryan R, Guarino M, Petrelli NJ, Elder D, ... ... Herlyn M, et al. Abstract 1182: Patient derived xenograft (PDX) of human melanoma to predict clinical responses Cancer Research. 74: 1182-1182. DOI: 10.1158/1538-7445.Am2014-1182 |
0.462 |
|
| 2014 |
Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, et al. 93 A stress induced early innate response causes multi-drug tolerance in melanoma European Journal of Cancer. 50: 34-34. DOI: 10.1016/S0959-8049(14)70219-9 |
0.491 |
|
| 2014 |
Somasundaram R, Facompre N, Herlyn M. Melanoma Subpopulations with Cancer Stem Cell Phenotypes Cancer Stem Cells. 223-234. DOI: 10.1002/9781118356203.ch17 |
0.343 |
|
| 2013 |
O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discovery. 3: 1378-93. PMID 24104062 DOI: 10.1158/2159-8290.Cd-13-0005 |
0.313 |
|
| 2013 |
Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, ... ... Herlyn M, et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Reports. 4: 1090-9. PMID 24055054 DOI: 10.1016/J.Celrep.2013.08.023 |
0.398 |
|
| 2013 |
Rasanen K, Sriswasdi S, Valiga A, Tang HY, Zhang G, Perego M, Somasundaram R, Li L, Speicher K, Klein-Szanto AJ, Basu D, Rustgi AK, Speicher DW, Herlyn M. Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Molecular & Cellular Proteomics : McP. 12: 3778-92. PMID 24037664 DOI: 10.1074/Mcp.M113.029587 |
0.616 |
|
| 2013 |
Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL, Diehl JA. The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Molecular and Cellular Biology. 33: 4422-33. PMID 24019069 DOI: 10.1128/Mcb.00706-13 |
0.36 |
|
| 2013 |
Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND, Weinstein GS, Nakagawa H, Diehl JA, Rustgi AK, Herlyn M. EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. Molecular Cancer Therapeutics. 12: 2176-86. PMID 23939378 DOI: 10.1158/1535-7163.Mct-12-1210 |
0.441 |
|
| 2013 |
Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, Herlyn M, Gimotty P, Nakagawa H, Rustgi AK. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis. 2: e59. PMID 23917221 DOI: 10.1038/oncsis.2013.17 |
0.323 |
|
| 2013 |
Kwak J, Gallagher M, Ozdener MH, Wysocki CJ, Goldsmith BR, Isamah A, Faranda A, Fakharzadeh SS, Herlyn M, Johnson AT, Preti G. Volatile biomarkers from human melanoma cells. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 931: 90-6. PMID 23770738 DOI: 10.1016/J.Jchromb.2013.05.007 |
0.328 |
|
| 2013 |
Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, ... ... Herlyn M, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 23: 811-25. PMID 23764003 DOI: 10.1016/J.Ccr.2013.05.003 |
0.42 |
|
| 2013 |
Wang T, Herlyn M. The macrophage: a new factor in UVR-induced melanomagenesis. The Journal of Investigative Dermatology. 133: 1711-3. PMID 23760048 DOI: 10.1038/Jid.2013.93 |
0.318 |
|
| 2013 |
Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Research. 73: 4383-94. PMID 23651636 DOI: 10.1158/0008-5472.Can-12-3385 |
0.411 |
|
| 2013 |
Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Reports. 3: 1252-65. PMID 23562156 DOI: 10.1016/J.Celrep.2013.03.004 |
0.582 |
|
| 2013 |
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell & Melanoma Research. 26: E8-E14. PMID 23531109 DOI: 10.1111/Pcmr.12099 |
0.354 |
|
| 2013 |
Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. Plos One. 8: e59588. PMID 23527225 DOI: 10.1371/Journal.Pone.0059588 |
0.442 |
|
| 2013 |
Swoboda RK, Herlyn M. There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis. Experimental Dermatology. 22: 303-6. PMID 23489578 DOI: 10.1111/Exd.12117 |
0.306 |
|
| 2013 |
Li L, Fukunaga-Kalabis M, Herlyn M. Isolation, characterization, and differentiation of human multipotent dermal stem cells. Methods in Molecular Biology (Clifton, N.J.). 989: 235-46. PMID 23483399 DOI: 10.1007/978-1-62703-330-5_18 |
0.32 |
|
| 2013 |
Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1784-94. PMID 23403634 DOI: 10.1158/1078-0432.Ccr-12-2518 |
0.432 |
|
| 2013 |
Wang T, Somasundaram R, Herlyn M. Combination therapy of immunocytokines with ipilimumab: a cure for melanoma? The Journal of Investigative Dermatology. 133: 595-6. PMID 23399823 DOI: 10.1038/Jid.2012.433 |
0.351 |
|
| 2013 |
Somasundaram R, Herlyn M. Relapse of melanoma after successful adoptive T-cell therapy: escape through inflammation-induced phenotypic melanoma cell plasticity. Pigment Cell & Melanoma Research. 26: 2-4. PMID 23387000 DOI: 10.1111/Pcmr.12038 |
0.481 |
|
| 2013 |
Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Molecular Cancer Research : McR. 11: 219-29. PMID 23303345 DOI: 10.1158/1541-7786.Mcr-12-0547-T |
0.576 |
|
| 2013 |
Balaburski G, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL, Yen T, George DL, Murphy ME. Abstract 1683: Autophagy inhibition for cancer therapy. Cancer Research. 73: 1683-1683. DOI: 10.1158/1538-7445.Am2013-1683 |
0.508 |
|
| 2013 |
Kagawa S, Nakagawa K, Natsuizaka M, Kinugasa H, Whelan KA, Chang S, Subramanian H, Ohashi S, Klein-Szanto AJ, Gimotty PA, Diehl JA, Herlyn M, Nakagawa H, Rustgi AK. 677 Inactivation of the Retinoblastoma Protein-Dependent Senescence Checkpoint Functions Permits Notch1 to Gain Oncogenic Tumor Promoting Activity Gastroenterology. 144: S-124. DOI: 10.1016/S0016-5085(13)60444-8 |
0.43 |
|
| 2013 |
Natsuizaka M, Kagawa S, Whelan KA, Chang S, Kinugasa H, Ohashi S, Naganuma S, Sakamoto N, Klein-Szanto AJ, Gimotty PA, Diehl JA, Herlyn M, Rustgi AK, Nakagawa H. 237 Transforming Growth Factor-β and Notch1 Cooperate to Repress NOTCH3 to Facilitate Epithelial-Mesenchymal Transition and Tumor Initiating Capability in Esophageal Squamous Cell Carcinoma Gastroenterology. 144: S-52. DOI: 10.1016/S0016-5085(13)60183-3 |
0.355 |
|
| 2013 |
Fukunaga-Kalabis M, Hristova D, Wang J, Li L, Herlyn M. Wnt7a opposes Notch pathway to specify neural crest-like stem cell fate toward the melanocytic lineage in human skin Journal of Dermatological Science. 69. DOI: 10.1016/J.Jdermsci.2012.11.485 |
0.318 |
|
| 2012 |
Maurer M, Somasundaram R, Herlyn M, Wagner SN. Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches. Oncoimmunology. 1: 1454-1456. PMID 23243627 DOI: 10.4161/Onci.21357 |
0.411 |
|
| 2012 |
Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Biology Open. 1: 516-26. PMID 23213444 DOI: 10.1242/Bio.20121149 |
0.353 |
|
| 2012 |
Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell. 22: 331-44. PMID 22975376 DOI: 10.1016/J.Ccr.2012.07.015 |
0.372 |
|
| 2012 |
Fukunaga-Kalabis M, Herlyn M. Beyond ABC: another mechanism of drug resistance in melanoma side population. The Journal of Investigative Dermatology. 132: 2317-9. PMID 22971921 DOI: 10.1038/Jid.2012.220 |
0.37 |
|
| 2012 |
Räsänen K, Herlyn M. Paracrine signaling between carcinoma cells and mesenchymal stem cells generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer Discovery. 2: 775-7. PMID 22969117 DOI: 10.1158/2159-8290.Cd-12-0312 |
0.344 |
|
| 2012 |
Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Advances in Pharmacology (San Diego, Calif.). 65: 335-59. PMID 22959031 DOI: 10.1016/B978-0-12-397927-8.00011-7 |
0.471 |
|
| 2012 |
Facompre N, Nakagawa H, Herlyn M, Basu D. Stem-like cells and therapy resistance in squamous cell carcinomas. Advances in Pharmacology (San Diego, Calif.). 65: 235-65. PMID 22959028 DOI: 10.1016/B978-0-12-397927-8.00008-7 |
0.367 |
|
| 2012 |
Tchou J, Kossenkov AV, Chang L, Satija C, Herlyn M, Showe LC, Puré E. Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles. Bmc Medical Genomics. 5: 39. PMID 22954256 DOI: 10.1186/1755-8794-5-39 |
0.337 |
|
| 2012 |
Zhang G, Herlyn M. Human nevi: no longer precursors of melanomas? The Journal of Investigative Dermatology. 132: 2133-4. PMID 22895446 DOI: 10.1038/Jid.2012.183 |
0.583 |
|
| 2012 |
Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W, Jiang H, Herlyn M, Liu H, et al. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Organic & Biomolecular Chemistry. 10: 7402-17. PMID 22875039 DOI: 10.1039/C2Ob26081F |
0.335 |
|
| 2012 |
John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. The Journal of Investigative Dermatology. 132: 2818-27. PMID 22810307 DOI: 10.1038/Jid.2012.237 |
0.39 |
|
| 2012 |
Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nature Medicine. 18: 853-4. PMID 22673991 DOI: 10.1038/Nm.2775 |
0.342 |
|
| 2012 |
Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, et al. Genomic characterisation of acral melanoma cell lines. Pigment Cell & Melanoma Research. 25: 488-92. PMID 22578220 DOI: 10.1111/J.1755-148X.2012.01016.X |
0.388 |
|
| 2012 |
Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler J, Marmorstein R. Identification of a novel family of BRAF(V600E) inhibitors. Journal of Medicinal Chemistry. 55: 5220-30. PMID 22537109 DOI: 10.1021/Jm3004416 |
0.336 |
|
| 2012 |
Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu X, Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell & Melanoma Research. 25: 493-505. PMID 22498258 DOI: 10.1111/J.1755-148X.2012.01005.X |
0.572 |
|
| 2012 |
Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfistershammer K, Gschaider M, Lai CY, Hsu MY, Herlyn M, Stingl G, Wagner SN. Targeting CD20 in melanoma patients at high risk of disease recurrence. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1056-62. PMID 22354376 DOI: 10.1038/Mt.2012.27 |
0.322 |
|
| 2012 |
Slipicevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala Journal of Medical Sciences. 117: 237-43. PMID 22339359 DOI: 10.3109/03009734.2012.658977 |
0.348 |
|
| 2012 |
Berking C, Herlyn M. Experimental induction of human atypical melanocytic lesions and melanoma in ultraviolet-irradiated human skin grafted to immunodeficient mice. Methods in Molecular Medicine. 61: 71-84. PMID 22323252 DOI: 10.1385/1-59259-145-0:71 |
0.332 |
|
| 2012 |
Lee JT, Herlyn M. MEK'ing the most of p53 reactivation therapy in melanoma. The Journal of Investigative Dermatology. 132: 263-5. PMID 22241441 DOI: 10.1038/Jid.2011.362 |
0.366 |
|
| 2012 |
Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nature Protocols. 7: 235-46. PMID 22240585 DOI: 10.1038/Nprot.2011.437 |
0.323 |
|
| 2012 |
Li L, Fukunaga-Kalabis M, Herlyn M. Isolation and cultivation of dermal stem cells that differentiate into functional epidermal melanocytes. Methods in Molecular Biology (Clifton, N.J.). 806: 15-29. PMID 22057442 DOI: 10.1007/978-1-61779-367-7_2 |
0.335 |
|
| 2012 |
Hsu MY, Herlyn M. Cultivation of normal human epidermal melanocytes. Methods in Molecular Medicine. 2: 9-20. PMID 21359729 DOI: 10.1385/0-89603-335-X:9 |
0.36 |
|
| 2012 |
Bewley AF, Rasanen K, Basu D, Herlyn M, Montone K. Epidermal Growth Factor Receptor Inhibition’s Effects on Invasion within Head and Neck Squamous Cell Carcinomas: Otolaryngology-Head and Neck Surgery. 147. DOI: 10.1177/0194599812451426A96 |
0.415 |
|
| 2012 |
Kagawa S, Natsuizaka M, Naganuma S, Kita Y, Natsugoe S, Chang S, Subramanian H, Basu D, Klein-Szanto AJ, Herlyn M, Nakagawa H. Abstract 70: Loss of cellular senescence checkpoint functions reveals the oncogene characteristics of Notch1 in squamous cell carcinomas Cancer Research. 72: 70-70. DOI: 10.1158/1538-7445.Am2012-70 |
0.475 |
|
| 2012 |
Herlyn M, Villanueva J. Abstract IA8: BRAF and MEK resistance in melanoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-Ia8 |
0.436 |
|
| 2012 |
Krepler C, Herlyn M, Villanueva J, Samatar A, Chen Y, Halloran M, Samanta M, He X, Vultur A, Wubbenhorst B, Nathanson K. Abstract B12: PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas Clinical Cancer Research. 18: B12-B12. DOI: 10.1158/1078-0432.Mechres-B12 |
0.324 |
|
| 2012 |
Herlyn M. Randy Lomax - the passionate melanoma advocate and champion of the Melanoma Research Foundation Pigment Cell and Melanoma Research. DOI: 10.1111/J.1755-148X.2012.01030.X |
0.301 |
|
| 2012 |
Natsuizaka M, Chang S, Kagawa S, Naganuma S, Ohashi S, Whelan KA, Wong GS, Vega ME, Yang Y, Gimotty PA, Diehl JA, Herlyn M, Nakagawa H. 252 CD44 Defines Highly Plastic Esophageal Squamous Cancer Cells With Tumor Initiating Capabilities Gastroenterology. 142: S-59. DOI: 10.1016/S0016-5085(12)60230-3 |
0.408 |
|
| 2012 |
Natsuizaka M, Naganuma S, Kagawa S, Ohashi S, Whelan KA, Chang S, Rhim AD, Klein-Szanto AJ, Diehl JA, Herlyn M, Nakagawa H. 251 A Functional Interplay Between TGF- and Notch Signaling Determines Esophageal Cancer Cell Fates Gastroenterology. 142: S-59. DOI: 10.1016/S0016-5085(12)60229-7 |
0.397 |
|
| 2012 |
Ge Y, Azuma R, Gekonge B, Lopez-Coral A, Xiao M, Zhang G, Xu X, Montaner LJ, Wei Z, Herlyn M, Wang T, Kaufman RE. Induction of metallothionein expression during monocyte to melanoma-associated macrophage differentiation Frontiers in Biology. 7: 359-367. DOI: 10.1007/S11515-012-1237-8 |
0.567 |
|
| 2011 |
Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Fibroblasts contribute to melanoma tumor growth and drug resistance. Molecular Pharmaceutics. 8: 2039-49. PMID 22067046 DOI: 10.1021/Mp200421K |
0.46 |
|
| 2011 |
Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman RA, Nakagawa M, Darling DS, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Herlyn M, Nakagawa H. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Research. 71: 6836-47. PMID 21890822 DOI: 10.1158/0008-5472.Can-11-0846 |
0.418 |
|
| 2011 |
Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. Journal of Visualized Experiments : Jove. PMID 21847077 DOI: 10.3791/2937 |
0.375 |
|
| 2011 |
Fukunaga-Kalabis M, Roesch A, Herlyn M. From cancer stem cells to tumor maintenance in melanoma. The Journal of Investigative Dermatology. 131: 1600-4. PMID 21654838 DOI: 10.1038/Jid.2011.159 |
0.405 |
|
| 2011 |
Basu D, Montone KT, Wang LP, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT, Rasanen K, Weinstein GS, Herlyn M. Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (Georgetown, Tex.). 10: 2008-16. PMID 21558812 DOI: 10.4161/Cc.10.12.15883 |
0.321 |
|
| 2011 |
Magnitsky S, Roesch A, Herlyn M, Glickson JD. In vivo and ex vivo MR imaging of slowly cycling melanoma cells. Magnetic Resonance in Medicine. 66: 1362-73. PMID 21523820 DOI: 10.1002/Mrm.22917 |
0.372 |
|
| 2011 |
Somasundaram R, Villanueva J, Herlyn M. Will engineered T cells expressing CD20 scFv eradicate Melanoma? Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 638-40. PMID 21455210 DOI: 10.1038/Mt.2011.46 |
0.466 |
|
| 2011 |
Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1658-63. PMID 21447722 DOI: 10.1158/1078-0432.Ccr-10-0174 |
0.386 |
|
| 2011 |
Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker E, Leonard JH, Herlyn M, Sturm RA. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene. 30: 3036-48. PMID 21358674 DOI: 10.1038/Onc.2011.33 |
0.453 |
|
| 2011 |
Herlyn M, Roesch A, Fukunaga-Kalabis M, Somasundaram R. Abstract SY12-02: Dynamic stemness in melanoma Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy12-02 |
0.442 |
|
| 2011 |
Villanueva J, Krepler C, Vultur A, Chen Y, He X, Wubbenhorst B, Nathanson KL, Herlyn M. Abstract 711: Understanding the mechanisms of resistance to BRAF inhibitors in melanoma Cancer Research. 71: 711-711. DOI: 10.1158/1538-7445.Am2011-711 |
0.431 |
|
| 2011 |
Lee JT, Brafford PA, Halloran MB, Schultz DC, Herlyn M. Abstract 587: B-Raf status predicts response to pharmacological activation of p53 in melanoma Cancer Research. 71: 587-587. DOI: 10.1158/1538-7445.Am2011-587 |
0.41 |
|
| 2011 |
Krepler C, Chunduru SK, He X, Gimotty PA, Vultur A, Villanueva J, Herlyn M. Abstract 5480: Effect of the Smac mimetic TL32711 in combination with TRAIL or TNF alpha on a panel of melanoma cell lines Cancer Research. 71: 5480-5480. DOI: 10.1158/1538-7445.Am2011-5480 |
0.417 |
|
| 2011 |
Räsänen KA, Basu D, Montone K, Zhang G, Rustgi A, Herlyn M. Abstract 523: Modeling the crosstalk between head and neck carcinomas and fibroblasts that underlies malignant invasion and drug resistance Cancer Research. 71: 523-523. DOI: 10.1158/1538-7445.Am2011-523 |
0.513 |
|
| 2011 |
Peng H, Hou Z, He M, Kebebew E, Orntoft TF, Herlyn M, Caton AJ, Fredericks WJ, Malkowicz B, Rauscher FJ. Abstract 5219: The LIM protein LIMD2 functions as an effector and biomarker for metastasis in multiple tumor types Cancer Research. 71: 5219-5219. DOI: 10.1158/1538-7445.Am2011-5219 |
0.32 |
|
| 2011 |
Natsuizaka M, Ohashi S, Naganuma S, Kalman RA, Ohyama A, Rhoades B, Vega ME, Stairs DB, Klein-Szanto AJ, Diehl JA, Basu D, Herlyn M, Pear WS, Nakagawa H. Abstract 5194: Notch regulates squamous differentiation, cell plasticity and tumor heterogeneity in esophageal carcinoma Cancer Research. 71: 5194-5194. DOI: 10.1158/1538-7445.Am2011-5194 |
0.462 |
|
| 2011 |
Zhang G, Herlyn M. Abstract 1244: The requirement of autophagy pathway for drug-induced senescence in human melanoma cells by AZD1152 Cancer Research. 71: 1244-1244. DOI: 10.1158/1538-7445.Am2011-1244 |
0.632 |
|
| 2011 |
Tchou J, Satija C, Zhang P, Bi Y, Davuluri R, Chen H, Majumdar R, Mies C, Herlyn M, Pure E. P1-03-09: Significance of FAP, SMA and CD31 Expression in the Stroma of Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-03-09 |
0.391 |
|
| 2011 |
Ohashi S, Natsuizaka M, Nakagawa M, Kalman RA, Chang S, Vega ME, Kalabis J, Stairs DB, Klein-Szanto AJ, Diehl JA, Herlyn M, Nakagawa H. EGFR and Notch Determine Esophageal Cell Fates Through an Antagonistic Crosstalk Gastroenterology. 140: S-165-S-166. DOI: 10.1016/S0016-5085(11)60670-7 |
0.335 |
|
| 2010 |
Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomarkers : Section a of Disease Markers. 9: 267-86. PMID 22112480 DOI: 10.3233/Cbm-2011-0164 |
0.402 |
|
| 2010 |
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, ... ... Herlyn M, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18: 683-95. PMID 21156289 DOI: 10.1016/J.Ccr.2010.11.023 |
0.375 |
|
| 2010 |
Han MJ, Wang H, Beer LA, Tang HY, Herlyn M, Speicher DW. A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics. 10: 4450-62. PMID 21136598 DOI: 10.1002/Pmic.200900549 |
0.42 |
|
| 2010 |
Herlyn M, Nathanson KL. Taking the guesswork out of uveal melanoma. The New England Journal of Medicine. 363: 2256-7. PMID 21083377 DOI: 10.1056/Nejme1010681 |
0.399 |
|
| 2010 |
Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell & Melanoma Research. 23: 820-7. PMID 20973932 DOI: 10.1111/j.1755-148X.2010.00763.x |
0.327 |
|
| 2010 |
Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB, Diehl JA. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 18: 329-40. PMID 20951943 DOI: 10.1016/J.Ccr.2010.08.012 |
0.31 |
|
| 2010 |
Vultur A, Villanueva J, Herlyn M. BRAF inhibitor unveils its potential against advanced melanoma. Cancer Cell. 18: 301-2. PMID 20951940 DOI: 10.1016/J.Ccr.2010.10.001 |
0.374 |
|
| 2010 |
Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu L, Klein-Szanto AJ, Herlyn M, Diehl JA, Katz JP, Pear WS, Seykora JT, Nakagawa H. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology. 139: 2113-23. PMID 20801121 DOI: 10.1053/J.Gastro.2010.08.040 |
0.346 |
|
| 2010 |
Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 29: 6115-24. PMID 20729912 DOI: 10.1038/Onc.2010.350 |
0.445 |
|
| 2010 |
Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn M, Han M, Nakagawa H, Rustgi AK. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proceedings of the National Academy of Sciences of the United States of America. 107: 11026-31. PMID 20534479 DOI: 10.1073/Pnas.0914295107 |
0.409 |
|
| 2010 |
Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim SB, Herlyn M, Diehl JA, Gimotty P, Rustgi AK. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Research. 70: 5281-92. PMID 20516120 DOI: 10.1158/0008-5472.Can-10-0704 |
0.316 |
|
| 2010 |
Natsuizaka M, Ohashi S, Wong GS, Ahmadi A, Kalman RA, Budo D, Klein-Szanto AJ, Herlyn M, Diehl JA, Nakagawa H. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis. 31: 1344-53. PMID 20513670 DOI: 10.1093/Carcin/Bgq108 |
0.336 |
|
| 2010 |
Basu D, Nguyen TT, Montone KT, Zhang G, Wang LP, Diehl JA, Rustgi AK, Lee JT, Weinstein GS, Herlyn M. Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene. 29: 4170-82. PMID 20498638 DOI: 10.1038/Onc.2010.170 |
0.617 |
|
| 2010 |
Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 141: 583-94. PMID 20478252 DOI: 10.1016/J.Cell.2010.04.020 |
0.451 |
|
| 2010 |
Zabierowski SE, Herlyn M. Embryonic stem cells as a model for studying melanocyte development. Methods in Molecular Biology (Clifton, N.J.). 584: 301-16. PMID 19907984 DOI: 10.1007/978-1-60761-369-5_16 |
0.336 |
|
| 2010 |
Degenhardt Y, Huang J, Greshock J, Horiates G, Nathanson K, Yang X, Herlyn M, Weber B. Distinct MHC gene expression patterns during progression of melanoma. Genes, Chromosomes & Cancer. 49: 144-54. PMID 19862823 DOI: 10.1002/Gcc.20728 |
0.348 |
|
| 2010 |
Wagner SN, Somasundaram R, Pinc A, Van Belle PA, Wagner C, Hoermann M, Karanikas G, Stingl G, Elder D, Herlyn M. CD20-immunotargeting of malignant melanoma. Journal of Clinical Oncology. 28: 8565-8565. DOI: 10.1200/Jco.2010.28.15_Suppl.8565 |
0.389 |
|
| 2010 |
Rustgi AK, Stairs DB, Grugan KD, Wong GS, Vega ME, Kalabis J, Nakagawa H, Gimotty PA, Klein-Szanto AJ, Diehl JA, Herlyn M. Abstract CN04-03: Esophageal cancer and the tumor microenvironment Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-Cn04-03 |
0.375 |
|
| 2010 |
Li B, Palma MD, Nathanson KL, Xu G, Smalley K, Herlyn M. Abstract 659: Overexpression of TPX2 accelerates cell cycle progression in melanoma and is an indicator of response to Aurora A kinase inhibitors Cancer Research. 70: 659-659. DOI: 10.1158/1538-7445.Am10-659 |
0.462 |
|
| 2010 |
Natsuizaka M, Kalman RA, Ohashi S, Takaoka M, Gimotty P, El-Deiry WS, Klein-Szanto A, Diehl JA, Herlyn M, Nakagawa H. Abstract 2294: IGF-independent regulation of EMT by insulin-like growth factor binding protein-3 in transformed human esophageal cells Cancer Research. 70: 2294-2294. DOI: 10.1158/1538-7445.Am10-2294 |
0.432 |
|
| 2010 |
Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT, Sosman J. Melanoma from bench to bedside: Meeting report from the 6th international melanoma congress (Pigment Cell and Melanoma Research (2010) 23, (14-26 )) Pigment Cell and Melanoma Research. 23: 303. DOI: 10.1111/J.1755-148X.2010.00682.X |
0.358 |
|
| 2009 |
Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, ... ... Herlyn M, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Research. 69: 5312-20. PMID 19549918 DOI: 10.1158/0008-5472.Can-08-3767 |
0.564 |
|
| 2009 |
Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. The American Journal of Pathology. 174: 2367-77. PMID 19389934 DOI: 10.2353/Ajpath.2009.081057 |
0.397 |
|
| 2009 |
Herlyn M. Driving in the melanoma landscape. Experimental Dermatology. 18: 506-8. PMID 19366372 DOI: 10.1111/J.1600-0625.2009.00872.X |
0.387 |
|
| 2009 |
Greshock J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, Zaks TZ. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes, Chromosomes & Cancer. 48: 419-28. PMID 19226609 DOI: 10.1002/Gcc.20651 |
0.373 |
|
| 2009 |
Santiago-Walker A, Li L, Haass NK, Herlyn M. Melanocytes: from morphology to application. Skin Pharmacology and Physiology. 22: 114-21. PMID 19188759 DOI: 10.1159/000178870 |
0.347 |
|
| 2009 |
Basu D, Herlyn M. Defining microenvironments within mouse models that enhance tumor aggressiveness. Cancer Biology & Therapy. 8: 380-1. PMID 19182538 DOI: 10.4161/Cbt.8.4.7739 |
0.337 |
|
| 2009 |
Smalley KS, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. International Journal of Cancer. 124: 1245-50. PMID 19089923 DOI: 10.1002/ijc.24129 |
0.365 |
|
| 2009 |
Vultur A, Herlyn M. Cracking the system: Melanoma complexity demands new therapeutic approaches Pigment Cell and Melanoma Research. 22: 4-5. PMID 19054340 DOI: 10.1111/J.1755-148X.2008.00527.X |
0.424 |
|
| 2009 |
Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 28: 85-94. PMID 18794803 DOI: 10.1038/Onc.2008.362 |
0.36 |
|
| 2009 |
Basu D, Nguyen T, Montone K, Zhang G, Wang LP, Rustgi A, Lee J, Weinstein G, Herlyn M. Abstract C77: A mesenchymal‐like subpopulation within squamous cell carcinomas with chemotherapy resistance and phenotypic plasticity Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C77 |
0.611 |
|
| 2009 |
Wong G, Michaylira CZ, Miller CG, Gutierrez CM, Stairs DB, Kalabis J, Nakagawa H, Diehl AJ, Herlyn M, Rustgi AK. Abstract C29: Periostin, a regulator of adhesion, is a novel effector of tumor invasion Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C29 |
0.327 |
|
| 2009 |
Wang T, Lopez‐Coral A, Roesch A, Huang C, Cha I, Hwang W, Meyer S, Vogt T, Herlyn M, Kaufman RE. Abstract A66: K12/SECTM1 promotes melanoma tumor progression via upregulation of integrin β3 expression Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A66 |
0.462 |
|
| 2009 |
Roesch A, Herlyn M. Melanoma cancer stem cells Cancer Stem Cells. 31-48. DOI: 10.1017/CBO9780511605536.004 |
0.347 |
|
| 2009 |
Ohashi S, Nakagawa M, Natsuizaka M, Stairs DB, Grugan KD, Kalabis J, Wong G, Yang Y, Klein-Szanto AJ, Herlyn M, Pear WS, Katz JP, Nakagawa H. 540 Epithelial Reconstitution Reveals Regulation of Differentiation and Cell Fate Decisions Through a Novel Interplay Between the Notch Signaling and Essential Cancer Genes in Esophageal Carcinogenesis Gastroenterology. 136: A-83. DOI: 10.1016/S0016-5085(09)60375-9 |
0.314 |
|
| 2009 |
Smalley KSM, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy International Journal of Cancer. 124: 1245-1250. DOI: 10.1002/Ijc.24129 |
0.473 |
|
| 2008 |
Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 1: 93-102. PMID 19308688 DOI: 10.1007/S12307-008-0009-0 |
0.385 |
|
| 2008 |
Kalabis J, Oyama K, Okawa T, Nakagawa H, Michaylira CZ, Stairs DB, Figueiredo JL, Mahmood U, Diehl JA, Herlyn M, Rustgi AK. A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. The Journal of Clinical Investigation. 118: 3860-9. PMID 19033657 DOI: 10.1172/Jci35012 |
0.331 |
|
| 2008 |
Harada H, Nakagawa H, Takaoka M, Lee J, Herlyn M, Diehl JA, Rustgi AK. Cleavage of MCM2 licensing protein fosters senescence in human keratinocytes. Cell Cycle (Georgetown, Tex.). 7: 3534-8. PMID 19001876 DOI: 10.4161/Cc.7.22.7043 |
0.378 |
|
| 2008 |
Kalabis J, Li G, Fukunaga-Kalabis M, Rustgi AK, Herlyn M. Endothelin-3 stimulates survival of goblet cells in organotypic cultures of fetal human colonic epithelium American Journal of Physiology - Gastrointestinal and Liver Physiology. 295. PMID 18832450 DOI: 10.1152/Ajpgi.90294.2008 |
0.381 |
|
| 2008 |
Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Molecular Cancer Therapeutics. 7: 2876-83. PMID 18790768 DOI: 10.1158/1535-7163.Mct-08-0431 |
0.371 |
|
| 2008 |
Lioni M, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, Herlyn M, Smalley KS. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Molecular Cancer Therapeutics. 7: 2866-75. PMID 18790767 DOI: 10.1158/1535-7163.Mct-08-0391 |
0.354 |
|
| 2008 |
Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Current Oncology Reports. 10: 439-46. PMID 18706274 DOI: 10.1007/S11912-008-0067-Y |
0.346 |
|
| 2008 |
Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Research. 68: 5743-52. PMID 18632627 DOI: 10.1158/0008-5472.Can-08-0235 |
0.434 |
|
| 2008 |
Zabierowski SE, Herlyn M. Melanoma stem cells: The dark seed of melanoma Journal of Clinical Oncology. 26: 2890-2894. PMID 18539969 DOI: 10.1200/Jco.2007.15.5465 |
0.406 |
|
| 2008 |
Xie P, Williams DS, Atilla-Gokcumen GE, Milk L, Xiao M, Smalley KS, Herlyn M, Meggers E, Marmorstein R. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. Acs Chemical Biology. 3: 305-16. PMID 18484710 DOI: 10.1021/Cb800039Y |
0.368 |
|
| 2008 |
Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS, Frankel AE. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Molecular Cancer Therapeutics. 7: 1218-26. PMID 18483309 DOI: 10.1158/1535-7163.Mct-08-0024 |
0.377 |
|
| 2008 |
Lee JT, Brafford P, Herlyn M. Unraveling the mysteries of IGF-1 signaling in melanoma Journal of Investigative Dermatology. 128: 1358-1360. PMID 18478012 DOI: 10.1038/Jid.2008.124 |
0.357 |
|
| 2008 |
Noma K, Smalley KS, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ, Nakagawa H, Herlyn M. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology. 134: 1981-93. PMID 18439605 DOI: 10.1053/J.Gastro.2008.02.061 |
0.361 |
|
| 2008 |
Zabierowski SE, Herlyn M. Learning the ABCs of Melanoma-Initiating Cells Cancer Cell. 13: 185-187. PMID 18328422 DOI: 10.1016/J.Ccr.2008.02.015 |
0.423 |
|
| 2008 |
Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, ... ... Herlyn M, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America. 105: 3041-6. PMID 18287029 DOI: 10.1073/Pnas.0711741105 |
0.395 |
|
| 2008 |
Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, Nuciforo PG, Cavallaro U. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium Cancer Research. 68: 1110-1118. PMID 18281486 DOI: 10.1158/0008-5472.Can-07-2897 |
0.377 |
|
| 2008 |
Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, ... ... Herlyn M, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research. 68: 664-73. PMID 18245465 DOI: 10.1158/0008-5472.Can-07-2615 |
0.419 |
|
| 2008 |
Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, Herlyn M, Maio M. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. Journal of Cellular Physiology. 215: 287-91. PMID 18205182 DOI: 10.1002/Jcp.21380 |
0.374 |
|
| 2008 |
Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 230-9. PMID 18172275 DOI: 10.1158/1078-0432.Ccr-07-1440 |
0.361 |
|
| 2008 |
Villanueva J, Herlyn M. Melanoma and the tumor microenvironment Current Oncology Reports. 10: 439-446. DOI: 10.1007/s11912-008-0067-y |
0.344 |
|
| 2007 |
Herlyn M, Halaban R, Ronai Z, Schuchter L, Berwick M, Pinkel D. Roadmap for new opportunities in melanoma research. Seminars in Oncology. 34: 566-76. PMID 18083380 DOI: 10.1053/J.Seminoncol.2007.09.004 |
0.307 |
|
| 2007 |
Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes & Development. 21: 2788-803. PMID 17974918 DOI: 10.1101/Gad.1544507 |
0.451 |
|
| 2007 |
Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B, Herlyn M. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene. 27: 2552-60. PMID 17968313 DOI: 10.1038/Sj.Onc.1210896 |
0.434 |
|
| 2007 |
Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 20: 458-65. PMID 17935489 DOI: 10.1111/J.1600-0749.2007.00410.X |
0.596 |
|
| 2007 |
Fukunaga-Kalabis M, Herlyn M. Unraveling mysteries of the multifunctional protein SPARC Journal of Investigative Dermatology. 127: 2497-2498. PMID 17934501 DOI: 10.1038/Sj.Jid.5701050 |
0.404 |
|
| 2007 |
Kumar KG, Liu J, Li Y, Yu D, Thomas-Tikhonenko A, Herlyn M, Fuchs SY. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biology & Therapy. 6: 1437-41. PMID 17873516 DOI: 10.4161/Cbt.6.9.4569 |
0.42 |
|
| 2007 |
Lee JT, Herlyn M. Old disease, new culprit: Tumor stem cells in cancer Journal of Cellular Physiology. 213: 603-609. PMID 17786956 DOI: 10.1002/Jcp.21252 |
0.419 |
|
| 2007 |
Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. The Journal of Molecular Diagnostics : Jmd. 9: 464-71. PMID 17690212 DOI: 10.2353/Jmoldx.2007.060191 |
0.348 |
|
| 2007 |
Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 11: 447-60. PMID 17482134 DOI: 10.1016/J.Ccr.2007.03.009 |
0.328 |
|
| 2007 |
Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Research. 67: 3177-84. PMID 17409425 DOI: 10.1158/0008-5472.Can-06-3312 |
0.381 |
|
| 2007 |
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Herlyn M, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/Ng1975 |
0.336 |
|
| 2007 |
Lioni M, Brafford P, Andl C, Rustgi A, El-Deiry W, Herlyn M, Smalley KS. Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. The American Journal of Pathology. 170: 709-21. PMID 17255337 DOI: 10.2353/Ajpath.2007.060343 |
0.383 |
|
| 2007 |
Smalley KSM, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels British Journal of Cancer. 96: 445-449. PMID 17245336 DOI: 10.1038/Sj.Bjc.6603596 |
0.357 |
|
| 2007 |
Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Research. 67: 209-17. PMID 17210701 DOI: 10.1158/0008-5472.Can-06-1538 |
0.371 |
|
| 2007 |
Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY. Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells Oncogene. 26: 1954-1958. PMID 17001349 DOI: 10.1038/Sj.Onc.1209994 |
0.396 |
|
| 2007 |
Herlyn M. Profiles and legacies: Farming cells to rebuild skin and melanoma Cancer Biology and Therapy. 6: 467-471. DOI: 10.4161/Cbt.6.3.4118 |
0.342 |
|
| 2007 |
Zabierowski SE, Herlyn M. Role of stem cells in melanoma progression: hopes for a better treatment Expert Review of Dermatology. 2: 191-201. DOI: 10.1586/17469872.2.2.191 |
0.402 |
|
| 2007 |
Smalley KS, Herlyn M, Flaherty KT. Targeting BRAF/MEK in melanoma: new hope or another false dawn? Expert Review of Dermatology. 2: 179-190. DOI: 10.1586/17469872.2.2.179 |
0.356 |
|
| 2007 |
Moser E, Shripad J, Quan P, Seidl H, Frank S, Liu Z, Fukunaga M, McDaid R, Kerl H, Herlyn M, Schaider H, Waldhoer M. The hCMV chemokine receptor US28 prevents melanoma growth Bmc Pharmacology. 7: A4. DOI: 10.1186/1471-2210-7-S2-A4 |
0.381 |
|
| 2007 |
Herlyn M, Smalley K, Haass N. INV 2 Development of targeted therapies of melanoma Melanoma Research. 17. DOI: 10.1097/00008390-200702000-00012 |
0.302 |
|
| 2006 |
Smalley KSM, Lioni M, Herlyn M. Life isn't flat: Taking cancer biology to the next dimension In Vitro Cellular and Developmental Biology - Animal. 42: 242-247. PMID 17163781 DOI: 10.1290/0604027.1 |
0.364 |
|
| 2006 |
King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, ... ... Herlyn M, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Research. 66: 11100-5. PMID 17145850 DOI: 10.1158/0008-5472.Can-06-2554 |
0.399 |
|
| 2006 |
Andl CD, Fargnoli BB, Okawa T, Bowser M, Takaoka M, Nakagawa H, Klein-Szanto A, Hua X, Herlyn M, Rustgi AK. Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo. Cancer Research. 66: 9878-85. PMID 17047049 DOI: 10.1158/0008-5472.Can-05-4157 |
0.356 |
|
| 2006 |
Lee JT, Herlyn M. Embryogenesis meets tumorigenesis Nature Medicine. 12: 882-884. PMID 16892028 DOI: 10.1038/Nm0806-882 |
0.337 |
|
| 2006 |
Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Molecular Cancer Therapeutics. 5: 1136-1144. PMID 16731745 DOI: 10.1158/1535-7163.MCT-06-0084 |
0.302 |
|
| 2006 |
Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G, Herlyn M, Xu X. Isolation of a novel population of multipotent adult stem cells from human hair follicles. The American Journal of Pathology. 168: 1879-88. PMID 16723703 DOI: 10.2353/Ajpath.2006.051170 |
0.327 |
|
| 2006 |
Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung LW. Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. The American Journal of Pathology. 168: 1405-12. PMID 16651608 DOI: 10.2353/Ajpath.2006.050874 |
0.367 |
|
| 2006 |
Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research. 66: 4182-90. PMID 16618740 DOI: 10.1158/0008-5472.Can-05-3589 |
0.606 |
|
| 2006 |
Smalley KSM, Herlyn M. Towards the targeted therapy of melanoma Mini-Reviews in Medicinal Chemistry. 6: 387-393. PMID 16613575 DOI: 10.2174/138955706776361402 |
0.37 |
|
| 2006 |
Fang D, Leishear K, Nguyen TK, Finko R, Cai K, Fukunaga M, Li L, Brafford PA, Kulp AN, Xu X, Smalley KS, Herlyn M. Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells (Dayton, Ohio). 24: 1668-77. PMID 16574754 DOI: 10.1634/Stemcells.2005-0414 |
0.346 |
|
| 2006 |
Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ, Velazquez OC, Herlyn M. Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 1009-11. PMID 16571776 DOI: 10.1096/Fj.05-4880Fje |
0.57 |
|
| 2006 |
Oka M, Nishigori C, Kageshita T, Hsu MY, Penmatcha S, Herlyn M. Expression of PKC isoforms in human melanocytic cells in situ. Journal of Dermatological Science. 41: 157-61. PMID 16406501 DOI: 10.1016/J.Jdermsci.2005.12.005 |
0.345 |
|
| 2006 |
Herlyn M. Molecular targets in melanoma: Strategies and challenges for diagnosis and therapy International Journal of Cancer. 118: 523-526. PMID 16258898 DOI: 10.1002/Ijc.21605 |
0.312 |
|
| 2006 |
Haass N, Smalley K, Contractor R, Sproesser K, Herlyn M. The novel MEK inhibitor AZD6244/ARRY142886 inhibits the growth of melanomas harboring the BRAFV600E mutation in vitro and in vivo Melanoma Research. 16. DOI: 10.1097/00008390-200609001-00169 |
0.334 |
|
| 2005 |
Smalley KSM, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics Annals of the New York Academy of Sciences. 1059: 16-25. PMID 16382039 DOI: 10.1196/Annals.1339.005 |
0.367 |
|
| 2005 |
Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma The Journal of Investigative Dermatology. Symposium Proceedings / the Society For Investigative Dermatology, Inc. [and] European Society For Dermatological Research.. 10: 153-163. PMID 16358819 DOI: 10.1111/J.1087-0024.2005.200407.X |
0.409 |
|
| 2005 |
Smalley KSM, Lioni M, Herlyn M. Targeting the stromal fibroblasts: A novel approach to melanoma therapy Expert Review of Anticancer Therapy. 5: 1069-1078. PMID 16336098 DOI: 10.1586/14737140.5.6.1069 |
0.362 |
|
| 2005 |
Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M, Liu ZJ. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. The Journal of Clinical Investigation. 115: 3166-76. PMID 16239965 DOI: 10.1172/Jci25001 |
0.598 |
|
| 2005 |
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research. 65: 9328-37. PMID 16230395 DOI: 10.1158/0008-5472.Can-05-1343 |
0.4 |
|
| 2005 |
Smalley KSM, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression Seminars in Cancer Biology. 15: 451-459. PMID 16043361 DOI: 10.1016/J.Semcancer.2005.06.002 |
0.376 |
|
| 2005 |
Li G, Herlyn M. Information sharing and collateral damage Trends in Molecular Medicine. 11: 350-352. PMID 16002338 DOI: 10.1016/J.Molmed.2005.06.009 |
0.354 |
|
| 2005 |
Hsu MY, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D. Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Reviews. 24: 251-63. PMID 15986135 DOI: 10.1007/S10555-005-1575-Y |
0.373 |
|
| 2005 |
Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience : a Journal and Virtual Library. 10: 2986-3001. PMID 15970553 DOI: 10.2741/1755 |
0.394 |
|
| 2005 |
McArdle L, Rafferty MM, Satyamoorthy K, Maelandsmo GM, Dervan PA, Herlyn M, Easty DJ. Microarray analysis of phosphatase gene expression in human melanoma British Journal of Dermatology. 152: 925-930. PMID 15888148 DOI: 10.1111/J.1365-2133.2005.06454.X |
0.357 |
|
| 2005 |
Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. The American Journal of Pathology. 166: 1541-54. PMID 15855653 DOI: 10.1016/S0002-9440(10)62370-X |
0.322 |
|
| 2005 |
Price KL, Herlyn M, Dent CL, Gewert DR, Linge C. The prevalence of interferon-alpha transcription defects in malignant melanoma. Melanoma Research. 15: 91-8. PMID 15846141 DOI: 10.1097/00008390-200504000-00002 |
0.302 |
|
| 2005 |
Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. Journal of Immunology (Baltimore, Md. : 1950). 174: 5856-63. PMID 15843590 DOI: 10.4049/Jimmunol.174.9.5856 |
0.427 |
|
| 2005 |
Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. The American Journal of Pathology. 166: 823-30. PMID 15743794 DOI: 10.1016/S0002-9440(10)62303-6 |
0.339 |
|
| 2004 |
Smalley KSM, Herlyn M. Loitering with intent: New evidence for the role of BRAF mutations in the proliferation of melanocytic lesions Journal of Investigative Dermatology. 123. PMID 15373800 DOI: 10.1111/J.0022-202X.2004.23430.X |
0.35 |
|
| 2004 |
Kim JW, Wong CW, Goldsmith JD, Song C, Fu W, Allion MB, Herlyn M, Al-Mehdi AB, Muschel RJ. Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic melanoma cells. Cancer Letters. 213: 203-12. PMID 15327836 DOI: 10.1016/J.Canlet.2004.03.042 |
0.314 |
|
| 2004 |
Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Research. 64: 4394-9. PMID 15231645 DOI: 10.1158/0008-5472.Can-04-0343 |
0.371 |
|
| 2004 |
Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells Journal of Biological Chemistry. 279: 40044-40052. PMID 15226295 DOI: 10.1074/Jbc.M404541200 |
0.357 |
|
| 2004 |
Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding β-catenin signaling Experimental Cell Research. 297: 142-151. PMID 15194432 DOI: 10.1016/J.Yexcr.2004.03.012 |
0.314 |
|
| 2004 |
van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP, Swart GW. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. The Journal of Investigative Dermatology. 122: 1293-301. PMID 15140234 DOI: 10.1111/J.0022-202X.2004.22531.X |
0.444 |
|
| 2004 |
Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, Lessin SR, Weber BL. Absence of BRAF mutations in UV-protected mucosal melanomas. Journal of Medical Genetics. 41: 270-2. PMID 15060100 DOI: 10.1136/Jmg.2003.016667 |
0.304 |
|
| 2004 |
Perlis C, Herlyn M. Recent Advances in Melanoma Biology Oncologist. 9: 182-187. PMID 15047922 DOI: 10.1634/Theoncologist.9-2-182 |
0.381 |
|
| 2004 |
Berking C, Takemoto R, Satyamoorthy K, Shirakawa T, Eskandarpour M, Hansson J, VanBelle PA, Elder DE, Herlyn M. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Research. 64: 807-11. PMID 14871803 DOI: 10.1158/0008-5472.Can-03-3438 |
0.372 |
|
| 2004 |
Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Möller H, Maczey E, Rassner G, Herlyn M, Garbe C. Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. Experimental Dermatology. 12: 296-306. PMID 12823444 DOI: 10.1034/J.1600-0625.2003.120310.X |
0.354 |
|
| 2003 |
Ruiter DJ, Herlyn M. [Melanoma-stroma interactions and melanoma progression]. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 1: 773-6. PMID 16281812 DOI: 10.1046/J.1439-0353.2003.03026.X |
0.417 |
|
| 2003 |
Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, Herlyn M, Bennett DC, Leonard JH, Sturm RA. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. The Journal of Investigative Dermatology. 121: 1150-9. PMID 14708619 DOI: 10.1046/J.1523-1747.2003.12562.X |
0.33 |
|
| 2003 |
Smalley KSM, Herlyn M. The Great Escape: Another Way for Melanoma to Leave Physiological Control? Journal of Investigative Dermatology. 121. PMID 14632176 DOI: 10.1046/J.1523-1747.2003.12506.X |
0.358 |
|
| 2003 |
Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene. 22: 6891-9. PMID 14534536 DOI: 10.1038/Sj.Onc.1206819 |
0.445 |
|
| 2003 |
Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis Oncogene. 22: 6524-6536. PMID 14528277 DOI: 10.1038/Sj.Onc.1206757 |
0.431 |
|
| 2003 |
Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research. 63: 5198-202. PMID 14500344 |
0.308 |
|
| 2003 |
Liu ZJ, Herlyn M. Slit-Robo: Neuronal guides signal in tumor angiogenesis Cancer Cell. 4: 1-2. PMID 12892705 DOI: 10.1016/S1535-6108(03)00166-1 |
0.336 |
|
| 2003 |
Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends in Immunology. 24: 335-42. PMID 12810110 DOI: 10.1016/S1471-4906(03)00116-9 |
0.365 |
|
| 2003 |
Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene. 22: 3162-71. PMID 12789292 DOI: 10.1038/Sj.Onc.1206455 |
0.409 |
|
| 2003 |
Velazquez OC, Herlyn M. The vascular phenotype of melanoma metastasis Clinical and Experimental Metastasis. 20: 229-235. PMID 12741681 DOI: 10.1023/A:1022987201264 |
0.4 |
|
| 2003 |
Kalabis J, Patterson MJ, Enders GH, Marian B, Iozzo RV, Rogler G, Gimotty PA, Herlyn M. Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 1115-7. PMID 12692084 DOI: 10.1096/Fj.02-0852Fje |
0.379 |
|
| 2003 |
Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M, Hsu MY, Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, ... ... Herlyn M, et al. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. The Journal of Investigative Dermatology. 120: 683-92. PMID 12648235 DOI: 10.1046/J.1523-1747.2003.12112.X |
0.354 |
|
| 2003 |
Zhang H, Satyamoorthy K, Herlyn M, Rosdahl I. All-trans retinoic acid (atRA) differentially induces apoptosis in matched primary and metastatic melanoma cells -- a speculation on damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis. 24: 185-91. PMID 12584166 DOI: 10.1093/Carcin/24.2.185 |
0.411 |
|
| 2003 |
Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: Implications for modulating arteriogenesis and angiogenesis Molecular and Cellular Biology. 23: 14-25. PMID 12482957 DOI: 10.1128/Mcb.23.1.14-25.2003 |
0.312 |
|
| 2002 |
Hsu MY, Meier F, Herlyn M. Melanoma development and progression: A conspiracy between tumor and host Differentiation. 70: 522-536. PMID 12492494 DOI: 10.1046/J.1432-0436.2002.700906.X |
0.426 |
|
| 2002 |
Bogenrieder T, Herlyn M. Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma Critical Reviews in Oncology/Hematology. 44: 1-15. PMID 12398996 DOI: 10.1016/S1040-8428(01)00196-2 |
0.406 |
|
| 2002 |
Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma Cancer Gene Therapy. 9: 807-812. PMID 12224020 DOI: 10.1038/Sj.Cgt.7700492 |
0.347 |
|
| 2002 |
Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma Cancer Biology and Therapy. 1: 14-17. PMID 12170758 DOI: 10.4161/Cbt.1.1.32 |
0.41 |
|
| 2002 |
Li G, Satyamoorthy K, Herlyn M. Dynamics of cell interactions and communications during melanoma development Critical Reviews in Oral Biology and Medicine. 13: 62-70. PMID 12097238 DOI: 10.1177/154411130201300107 |
0.422 |
|
| 2002 |
Velazquez OC, Snyder R, Liu ZJ, Fairman RM, Herlyn M. Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 16: 1316-8. PMID 12060671 DOI: 10.1096/Fj.01-1011Fje |
0.344 |
|
| 2001 |
McArdle L, Rafferty M, Mælandsmo GM, Bergin O, Farr CJ, Dervan PA, O'Loughlin S, Herlyn M, Easty DJ. Protein tyrosine phosphatase genes downregulated in melanoma Journal of Investigative Dermatology. 117: 1255-1260. PMID 11710941 DOI: 10.1046/J.0022-202X.2001.01534.X |
0.356 |
|
| 2001 |
Sauter ER, Tichansky D, Furth EE, Herlyn M. Tumor-associated antigen expression and growth requirements predict tumorigenesis in squamous cell carcinoma In Vitro Cellular and Developmental Biology - Animal. 37: 530-535. PMID 11669287 DOI: 10.1290/1071-2690(2001)037<0530:Taaeag>2.0.Co;2 |
0.451 |
|
| 2001 |
Nesbit M, Schaider H, Berking C, Shih DT, Hsu MY, McBrian M, Crombleholme TM, Elenitsas R, Buck C, Herlyn M. α5 and α2 integrin gene transfers mimic the PDGF-B-induced transformed phenotype of fibroblasts in human skin Laboratory Investigation. 81: 1263-1274. PMID 11555674 DOI: 10.1038/Labinvest.3780340 |
0.302 |
|
| 2001 |
Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene. 20: 4676-84. PMID 11498790 DOI: 10.1038/Sj.Onc.1204616 |
0.44 |
|
| 2001 |
Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells Journal of Immunology. 166: 6483-6490. PMID 11359798 DOI: 10.4049/Jimmunol.166.11.6483 |
0.403 |
|
| 2001 |
Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box - New clues to apoptosis and drug resistance in melanoma Trends in Molecular Medicine. 7: 191-194. PMID 11325619 DOI: 10.1016/S1471-4914(01)02013-5 |
0.37 |
|
| 2001 |
Sauter ER, Nesbit M, Tichansky D, Liu ZJ, Shirakawa T, Palazzo J, Herlyn M. Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental human squamous epithelium. International Journal of Cancer. 92: 374-81. PMID 11291074 DOI: 10.1002/ijc.1207 |
0.3 |
|
| 2001 |
Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M. Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. The American Journal of Pathology. 158: 943-53. PMID 11238042 DOI: 10.1016/S0002-9440(10)64041-2 |
0.387 |
|
| 2001 |
Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma Current Opinion in Oncology. 13: 117-123. PMID 11224709 DOI: 10.1097/00001622-200103000-00006 |
0.423 |
|
| 2000 |
Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society. 8: 480-93. PMID 11208175 DOI: 10.1046/J.1524-475X.2000.00480.X |
0.301 |
|
| 2000 |
Satyamoorthy K, Oka M, Herlyn M. An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin Pigment Cell Research. 13: 87-93. PMID 11041363 DOI: 10.1034/J.1600-0749.13.S8.16.X |
0.44 |
|
| 2000 |
Herlyn M, Barking C, Li G, Satyamoorthy K. Lessons from melanocyte development for understanding the biological events in naevus melanoma formation Melanoma Research. 10: 303-312. PMID 10985664 DOI: 10.1097/00008390-200008000-00001 |
0.429 |
|
| 2000 |
Chandler LA, Doukas J, Gonzalez AM, Hoganson DK, Gu DL, Ma C, Nesbit M, Crombleholme TM, Herlyn M, Sosnowski BA, Pierce GF. FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 153-60. PMID 10947943 DOI: 10.1006/Mthe.2000.0102 |
0.301 |
|
| 2000 |
Fredericks WJ, Ayyanathan K, Herlyn M, Friedman JR, Rauscher FJ. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Molecular and Cellular Biology. 20: 5019-31. PMID 10866659 DOI: 10.1128/Mcb.20.14.5019-5031.2000 |
0.337 |
|
| 2000 |
St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Therapy. 7: 749-56. PMID 10830722 DOI: 10.1038/Sj.Cgt.7700166 |
0.303 |
|
| 2000 |
Li G, Herlyn M. Dynamics of intercellular communication during melanoma development Molecular Medicine Today. 6: 163-169. PMID 10740255 DOI: 10.1016/S1357-4310(00)01692-0 |
0.375 |
|
| 2000 |
Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, Elder DE, Schaumburg-Lever G, Garbe C, Walz TM, Donatien P, Crombleholme TM, Herlyn M. Human melanoma progression in skin reconstructs: Biological significance of bFGF American Journal of Pathology. 156: 193-200. PMID 10623667 DOI: 10.1016/S0002-9440(10)64719-0 |
0.377 |
|
| 1999 |
Satyamoorthy K, Meier F, Hsu MY, Berking C, Herlyn M. Human xenografts, human skin and skin reconstructs for studies in melanoma development and progression. Cancer Metastasis Reviews. 18: 401-5. PMID 10721493 DOI: 10.1023/A:1006333627271 |
0.374 |
|
| 1999 |
Hsu JJ, Hsu MY, Sorger T, Herlyn M, Levine EM. Heparin/endothelial cell growth supplement regulates matrix gene expression and prolongs life span of vascular smooth muscle cells through modulation of interleukin-1 In Vitro Cellular and Developmental Biology - Animal. 35: 647-654. PMID 10614876 DOI: 10.1007/S11626-999-0105-6 |
0.322 |
|
| 1999 |
Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E, McBrian M, Gupta AR, Eck SL, Herlyn M. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene. 18: 6469-76. PMID 10597249 DOI: 10.1038/Sj.Onc.1203066 |
0.372 |
|
| 1999 |
Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. Up-regulation of ephrin-A1 during melanoma progression. International Journal of Cancer. 84: 494-501. PMID 10502726 DOI: 10.1002/(Sici)1097-0215(19991022)84:5<494::Aid-Ijc8>3.0.Co;2-O |
0.351 |
|
| 1999 |
Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 96: 9689-94. PMID 10449755 DOI: 10.1073/Pnas.96.17.9689 |
0.435 |
|
| 1999 |
Herlyn M. Endothelial cells as targets for tumor therapy: Editorial Journal of Immunotherapy. 22: 185. PMID 10335478 DOI: 10.1097/00002371-199905000-00001 |
0.374 |
|
| 1999 |
Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, Enders GH. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Molecular and Cellular Biology. 19: 3916-28. PMID 10207115 DOI: 10.1128/Mcb.19.5.3916 |
0.302 |
|
| 1999 |
Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn M. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. International Journal of Cancer. Journal International Du Cancer. 84: 160-8. PMID 10096249 DOI: 10.1002/(Sici)1097-0215(19990420)84:2<160::Aid-Ijc12>3.0.Co;2-R |
0.305 |
|
| 1999 |
Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M, Ronai Z. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells Molecular Carcinogenesis. 24: 64-69. PMID 10029412 DOI: 10.1002/(Sici)1098-2744(199901)24:1<64::Aid-Mc9>3.0.Co;2-2 |
0.339 |
|
| 1998 |
Sauter ER, Klein-Szanto AJ, Atillasoy E, Montone KT, Goodrow T, Binder RL, Seykora JT, Herlyn M. Ultraviolet B-induced squamous epithelial and melanocytic cell changes in a xenograft model of cancer development in human skin. Molecular Carcinogenesis. 23: 168-74. PMID 9833777 DOI: 10.1002/(Sici)1098-2744(199811)23:3<168::Aid-Mc5>3.0.Co;2-E |
0.363 |
|
| 1998 |
Sauter ER, Herlyn M. Molecular biology of human melanoma development and progression Molecular Carcinogenesis. 23: 132-143. PMID 9833774 DOI: 10.1002/(Sici)1098-2744(199811)23:3<132::Aid-Mc2>3.0.Co;2-1 |
0.384 |
|
| 1998 |
Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, Herlyn M. Molecular events in melanoma development and progression. Frontiers in Bioscience : a Journal and Virtual Library. 3: D1005-10. PMID 9740553 DOI: 10.2741/A341 |
0.458 |
|
| 1998 |
Rauscher FJ, Morris JF, Fredericks WJ, Lopez-Guisa J, Balakrishnan C, Jost M, Herlyn M, Rodeck U. Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein. Hybridoma. 17: 191-8. PMID 9627060 DOI: 10.1089/Hyb.1998.17.191 |
0.325 |
|
| 1998 |
Ronai Z, Yang YM, Fuchs SY, Adler V, Sardana M, Herlyn M. ATF2 confers radiation resistance to human melanoma cells Oncogene. 16: 523-531. PMID 9484842 DOI: 10.1038/Sj.Onc.1201566 |
0.4 |
|
| 1998 |
Oka M, Nesbit M, Satyamoorthy K, Ichihashi M, Herlyn M. Metastatic but not primary melanoma cells escape from neutrophil attack induced by adenoviral gene transfer of interleukin-8 Journal of Dermatological Science. 16: S182. DOI: 10.1016/S0923-1811(98)84085-1 |
0.341 |
|
| 1998 |
Meier F, Hsu M, Shih D, Satyamoorthy K, Van Belle P, Beuerman R, Seykora J, Elder D, Herlyn M. In vitro skin reconstructs to study cell-cell and cell-matrix interactions in human melanoma Journal of Dermatological Science. 16: S97. DOI: 10.1016/S0923-1811(98)83576-7 |
0.368 |
|
| 1997 |
Atillasoy ES, Elenitsas R, Sauter ER, Soballe PW, Herlyn M. UVB induction of epithelial tumors in human skin using a RAG-1 mouse xenograft model. The Journal of Investigative Dermatology. 109: 704-9. PMID 9406808 DOI: 10.1111/1523-1747.Ep12340661 |
0.326 |
|
| 1997 |
Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M. Melanoma cell lines from different stages of progression and their biological and molecular analyses Melanoma Research. 7: S43. DOI: 10.1097/00008390-199708001-00007 |
0.404 |
|
| 1997 |
Oka M, Nesbit M, Satyamoorthy K, Hsu M, Glatt B, Ichihashi M, Herlyn M. 153 Utility of adenoviruses as gene expression vectors in melanocytic cells Journal of Dermatological Science. 15: 128. DOI: 10.1016/S0923-1811(97)81852-X |
0.3 |
|
| 1996 |
Juhász I, Simon M, Herlyn M, Hunyadi J. Repopulation of Langerhans cells during wound healing in an experimental human skin/SCID mouse model Immunology Letters. 52: 125-128. PMID 8905406 DOI: 10.1016/0165-2478(96)02596-5 |
0.328 |
|
| 1996 |
Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 19: 192-205. PMID 8811494 DOI: 10.1097/00002371-199605000-00004 |
0.413 |
|
| 1995 |
Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis International Journal of Cancer. 60: 129-136. PMID 7814145 DOI: 10.1002/Ijc.2910600119 |
0.381 |
|
| 1994 |
Hijiya N, Zhang J, Ratajczak MZ, Kant JA, Deriel K, Herlyn M, Zon G, Gewirtz AM. Biologic and therapeutic significance of MYB expression in human melanoma Proceedings of the National Academy of Sciences of the United States of America. 91: 4499-4503. PMID 8183937 DOI: 10.1073/Pnas.91.10.4499 |
0.417 |
|
| 1994 |
Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 7: 81-88. PMID 8066024 DOI: 10.1111/J.1600-0749.1994.Tb00025.X |
0.416 |
|
| 1994 |
Gratas C, Herlyn M, Becker D. Isolation and analysis of novel human melanocyte-specific cDNA clones Dna and Cell Biology. 13: 515-519. PMID 8024694 DOI: 10.1089/Dna.1994.13.515 |
0.32 |
|
| 1994 |
Shih LM, Elder DE, Hsu MY, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes American Journal of Pathology. 145: 837-845. PMID 7943174 |
0.323 |
|
| 1994 |
Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma In Vivo. 8: 113-123. PMID 7519892 |
0.331 |
|
| 1993 |
Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC. Mutation and expression of the p53 gene in malignant melanoma cell lines. International Journal of Cancer. 54: 693-9. PMID 8514460 DOI: 10.1002/Ijc.2910540427 |
0.36 |
|
| 1993 |
Valyi-Nagy I, Shih IM, Györfi T, Greenstein D, Juhasz I, Elder DE, Herlyn M. Spontaneous and induced differentiation of human melanoma cells. International Journal of Cancer. 54: 159-65. PMID 8478142 DOI: 10.1002/Ijc.2910540125 |
0.418 |
|
| 1993 |
Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients Journal of Experimental Medicine. 177: 989-998. PMID 8459226 DOI: 10.1084/Jem.177.4.989 |
0.303 |
|
| 1993 |
Iliopoulos D, Atkinson B, Saul SH, Herlyn M, Rodriguez-Martinez HA, West SL, Maislin G, Soloway RD, Strom BL. Differences in antigen expression between neoplastic and nonneoplastic gallbladder epithelium. An immunohistochemical study. Digestive Diseases and Sciences. 38: 155-60. PMID 8420749 DOI: 10.1007/Bf01296789 |
0.33 |
|
| 1993 |
Shih IM, Herlyn M. Role of growth factors and their receptors in the development and progression of melanoma Journal of Investigative Dermatology. 100. PMID 8381840 DOI: 10.1038/Jid.1993.76 |
0.434 |
|
| 1993 |
Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proceedings of the National Academy of Sciences of the United States of America. 90: 393-7. PMID 8380638 DOI: 10.1073/Pnas.90.2.393 |
0.403 |
|
| 1993 |
Easty DJ, Ganz SE, Farr CJ, Lai C, Herlyn M, Bennett DC. Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. The Journal of Investigative Dermatology. 101: 679-84. PMID 8228328 DOI: 10.1111/1523-1747.Ep12371675 |
0.354 |
|
| 1993 |
Yan HC, Juhasz I, Pilewski J, Murphy GF, Herlyn M, Albelda SM. Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules. The Journal of Clinical Investigation. 91: 986-96. PMID 7680673 DOI: 10.1172/Jci116320 |
0.349 |
|
| 1993 |
Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi R, Squarcina P, Herlyn M, Parmiani G. Recognition of lineage-specific antigens on melanoma and melanocytes by HLA-A2-restricted cytolytic T cell clones: 75 Melanoma Research. 3: 21. DOI: 10.1097/00008390-199303000-00071 |
0.302 |
|
| 1993 |
Herlyn M, Shih IM, Nesbit M, Soballe P, Rodeck U. Growth factors with autocrine and paracrine functions in melanoma progression and invasion: 72 Melanoma Research. 3: 20. DOI: 10.1097/00008390-199303000-00068 |
0.31 |
|
| 1992 |
Radrizzani M, Benedetti B, Castelli C, Longo A, Ferrara GB, Herlyn M, Parmiani G, Fossati G. Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions. International Journal of Cancer. 49: 823-30. PMID 1835714 DOI: 10.1002/Ijc.2910490605 |
0.301 |
|
| 1992 |
Valyi-Nagy I, Rodeck U, Kath R, Mancianti ML, Clark WH, Herlyn M. The human melanocyte system as a model for studies on tumor progression. Basic Life Sciences. 57: 315-26; discussion 3. PMID 1814292 DOI: 10.1007/978-1-4684-5994-4_26 |
0.402 |
|
| 1992 |
Williams NN, Györfi T, Iliopoulos D, Herlyn D, Greenstein D, Linnenbach AJ, Daly JM, Jensen P, Rodeck U, Herlyn M. Growth-factor-independence and invasive properties of colorectal carcinoma cells. International Journal of Cancer. Journal International Du Cancer. 50: 274-80. PMID 1730521 DOI: 10.1002/Ijc.2910500218 |
0.365 |
|
| 1992 |
Menrad A, Herlyn M. Tumor progression, biology, and host response in melanoma Current Opinion in Oncology. 4: 351-356. PMID 1591308 DOI: 10.1097/00001622-199204000-00018 |
0.44 |
|
| 1992 |
Graeven U, Herlyn M. In vitro growth patterns of normal human melanocytes and melanocytes from different stages of melanoma progression Journal of Immunotherapy. 12: 199-202. PMID 1445812 DOI: 10.1097/00002371-199210000-00012 |
0.357 |
|
| 1992 |
Graeven U, Rodeck U, Weinmann R, Herlyn M. Stable transfection of human malignant melanoma cells with basic fibroblast growth factor antisense cDNA Annals of the New York Academy of Sciences. 660: 293-294. PMID 1340139 DOI: 10.1111/J.1749-6632.1992.Tb21090.X |
0.392 |
|
| 1991 |
Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 88: 6028-32. PMID 2068080 DOI: 10.1073/Pnas.88.14.6028 |
0.335 |
|
| 1991 |
Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. The Journal of Investigative Dermatology. 97: 20-6. PMID 2056188 DOI: 10.1111/1523-1747.Ep12477822 |
0.342 |
|
| 1991 |
Herlyn D, Linnenbach A, Koprowski H, Herlyn M. Epitope- and antigen-specific cancer vaccines International Reviews of Immunology. 7: 245-257. PMID 1779173 DOI: 10.3109/08830189109114874 |
0.532 |
|
| 1991 |
Valyi-Nagy IT, Herlyn M. Regulation of growth and phenotype of normal human melanocytes in culture Cancer Treatment and Research. 54: 85-101. PMID 1673861 DOI: 10.1007/978-1-4615-3938-4_5 |
0.366 |
|
| 1991 |
Herlyn D, Adachi K, Koprowski H, Herlyn M. Experimental model of human melanoma metastases Cancer Treatment and Research. 54: 105-118. PMID 1673854 DOI: 10.1007/978-1-4615-3938-4_6 |
0.549 |
|
| 1990 |
Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U. Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro. Advances in Cancer Research. 54: 213-234. PMID 2404378 DOI: 10.1016/S0065-230X(08)60812-X |
0.38 |
|
| 1990 |
Howe CC, Kath R, Mancianti ML, Herlyn M, Mueller S, Cristofalo V. Expression and structure of human SPARC transcripts: SPARC mRNA is expressed by human cells involved in extracellular matrix production and some of these cells show an unusual expression pattern. Experimental Cell Research. 188: 185-91. PMID 2335186 DOI: 10.1016/0014-4827(90)90158-7 |
0.357 |
|
| 1990 |
Mancianti ML, Clark WH, Hayes FA, Herlyn M. Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype American Journal of Pathology. 136: 817-829. PMID 2327470 |
0.307 |
|
| 1990 |
Herlyn M. Human melanoma: Development and progression Cancer and Metastasis Review. 9: 101-112. PMID 2253310 DOI: 10.1007/Bf00046337 |
0.458 |
|
| 1990 |
Herlyn M, Menrad A, Koprowski H. Structure, function, and clinical significance of human tumor antigens Journal of the National Cancer Institute. 82: 1883-1889. PMID 2250310 DOI: 10.1093/Jnci/82.24.1883 |
0.5 |
|
| 1990 |
Rodeck U, Williams N, Murthy U, Herlyn M. Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-α Journal of Cellular Biochemistry. 44: 69-79. PMID 2250044 DOI: 10.1002/Jcb.240440202 |
0.363 |
|
| 1989 |
Iliopoulos D, Ernst C, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH, Koprowski H, Herlyn D. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the gd2/gd3 gangliosides Journal of the National Cancer Institute. 81: 440-444. PMID 2918552 DOI: 10.1093/Jnci/81.6.440 |
0.556 |
|
| 1989 |
Mancianti ML, Herlyn M. Tumor progression in melanoma: the biology of epidermal melanocytes in vitro Carcinogenesis; a Comprehensive Survey. 11: 369-386. PMID 2646021 |
0.36 |
|
| 1989 |
Jambrosic J, Mancianti ML, Ricciardi R, Sela BA, Koprowski H, Herlyn M. Transformation of normal human melanocytes and non-malignant nevus cells by adenovirus 12-SV40 hybrid virus International Journal of Cancer. 44: 1117-1123. PMID 2558080 DOI: 10.1002/Ijc.2910440630 |
0.547 |
|
| 1988 |
Herlyn M, Koprowski H. Melanoma antigens: Immunological and biological characterization and clinical significance Annual Review of Immunology. 6: 283-308. PMID 3289568 DOI: 10.1146/annurev.iy.06.040188.001435 |
0.406 |
|
| 1988 |
Rodeck U, Herlyn M. Characteristics of cultured human melanocytes from different stages of tumor progression Cancer Treatment and Research. 43: 3-16. PMID 2908575 DOI: 10.1007/978-1-4613-1751-7_1 |
0.454 |
|
| 1988 |
Linnenbach AJ, Huebner K, Reddy EP, Herlyn M, Parmiter AH, Nowell PC, Koprowski H. Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines. Proceedings of the National Academy of Sciences of the United States of America. 85: 74-8. PMID 2829178 DOI: 10.1073/Pnas.85.1.74 |
0.524 |
|
| 1988 |
Mancianti ML, Herlyn M, Weil D, Jambrosic J, Rodeck U, Becker D, Diamond L, Clark WH, Koprowski H. Growth and phenotypic characteristics of human nevus cells in culture. The Journal of Investigative Dermatology. 90: 134-41. PMID 2828480 DOI: 10.1111/1523-1747.ep12462099 |
0.51 |
|
| 1988 |
Herlyn M, Mancianti ML, Jambrosic J, Bolen JB, Koprowski H. Regulatory factors that determine growth and phenotype of normal human melanocytes. Experimental Cell Research. 179: 322-31. PMID 2461309 DOI: 10.1016/0014-4827(88)90271-6 |
0.51 |
|
| 1987 |
Donoso LA, Felberg NT, Edelberg K, Borlinghaus P, Herlyn M. Metastatic uveal melanoma: an ocular melanoma associated antigen in the serum of patients with metastatic disease. Journal of Immunoassay. 7: 273-83. PMID 3805289 DOI: 10.1080/01971528608060472 |
0.362 |
|
| 1987 |
Herlyn D, Powe J, Munz DL, Alavi A, Herlyn M, Meinken GE, Srivastava SC, Koprowski H. Radioimmunodetection of human tumor xenografts by monoclonal antibody F(ab')2 fragments. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 13: 401-5. PMID 3793494 DOI: 10.1016/0883-2897(86)90017-6 |
0.532 |
|
| 1987 |
Menssen HD, Herlyn M, Rodeck U, Koprowski H. Rapid dissociation of adherent human tumor cells by ultrasound Journal of Immunological Methods. 104: 1-6. PMID 3316390 DOI: 10.1016/0022-1759(87)90480-7 |
0.568 |
|
| 1987 |
Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowsk H. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. International Journal of Cancer. 40: 687-90. PMID 3316051 DOI: 10.1002/Ijc.2910400520 |
0.356 |
|
| 1987 |
Rodeck U, Herlyn M, Koprowski H. Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors Journal of Cellular Biochemistry. 35: 315-320. PMID 2831241 DOI: 10.1002/Jcb.240350406 |
0.517 |
|
| 1987 |
Rodeck U, Herlyn M, Leander K, Borlinghaus P, Koprowski H. A mucin containing the X, Y, and H type 2 carbohydrate determinants is shed by carcinoma cells. Hybridoma. 6: 389-401. PMID 2442094 DOI: 10.1089/Hyb.1987.6.389 |
0.475 |
|
| 1987 |
Ordonez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma Gynecologic Oncology. 26: 1-10. PMID 2431961 DOI: 10.1016/0090-8258(87)90065-5 |
0.332 |
|
| 1987 |
Herlyn M, Rodeck U, Koprowski H. Shedding Of Human Tumor-Associated Antigens in Vitro and in Vivo Advances in Cancer Research. 49: 189-221. DOI: 10.1016/S0065-230X(08)60798-8 |
0.566 |
|
| 1986 |
Balaban GB, Herlyn M, Clark WH, Nowell PC. Karyotypic evolution in human malignant melanoma Cancer Genetics and Cytogenetics. 19: 113-122. PMID 3940171 DOI: 10.1016/0165-4608(86)90378-X |
0.31 |
|
| 1986 |
Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH, Koprowski H. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. Febs Letters. 208: 17-22. PMID 3533633 DOI: 10.1016/0014-5793(86)81522-8 |
0.544 |
|
| 1986 |
Ross AH, Herlyn M, Maul GG, Koprowski H, Bothwell M, Chao M, Pleasure D, Sonnenfeld KH. The nerve growth factor receptor in normal and transformed neural crest cells Annals of the New York Academy of Sciences. 115-123. PMID 3032054 DOI: 10.1111/J.1749-6632.1986.Tb48067.X |
0.451 |
|
| 1986 |
Westermark B, Johnsson A, Paulsson Y, Betsholtz C, Heldin CH, Herlyn M, Rodeck U, Koprowski H. Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proceedings of the National Academy of Sciences of the United States of America. 83: 7197-200. PMID 3020539 DOI: 10.1073/Pnas.83.19.7197 |
0.552 |
|
| 1986 |
Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor and platelet-derived growth factor in cells bearing the appropriate surface receptor Proceedings of the National Academy of Sciences of the United States of America. 83: 3728-3732. PMID 3012531 DOI: 10.1073/Pnas.83.11.3728 |
0.463 |
|
| 1986 |
DeFreitas E, Suzuki H, Herlyn D, Lubeck M, Sears H, Herlyn M, Koprowski H. Human antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a gastrointestinal carcinoma antigen. Current Topics in Microbiology and Immunology. 119: 75-89. PMID 2867860 DOI: 10.1007/978-3-642-70675-2_6 |
0.496 |
|
| 1986 |
Ernst CS, Shen J, Litwin S, Herlyn M, Koprowski H, Sears HF. Multiparameter Evaluation of the Expression In Situ of Normal and Tumor-Associated Antigens in Human Colorectal Carcinoma Journal of the National Cancer Institute. 77: 387-395. DOI: 10.1093/Jnci/77.2.387 |
0.526 |
|
| 1985 |
Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells Cellular Immunology. 92: 105-114. PMID 4075410 DOI: 10.1016/0008-8749(85)90068-1 |
0.547 |
|
| 1985 |
Atkinson B, Ernst CS, Ghrist BFD, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z, Koprowski H. Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors Hybridoma. 4: 243-255. PMID 4043988 DOI: 10.1089/Hyb.1985.4.243 |
0.54 |
|
| 1985 |
Donoso LA, Folberg R, Edelberg K, Arbizo V, Atkinson B, Herlyn M. Tissue distribution and biochemical properties of an ocular melanoma-associated antigen. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 33: 1190-6. PMID 3905953 DOI: 10.1177/33.12.3905953 |
0.382 |
|
| 1985 |
Herlyn M, Blaszczyk M, Bennicelli J, Sears HF, Ernst C, Ross AH, Koprowski H. Selection of monoclonal antibodies detecting serodiagnostic human tumor markers. Journal of Immunological Methods. 80: 107-16. PMID 3859550 DOI: 10.1016/0022-1759(85)90169-3 |
0.504 |
|
| 1985 |
Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A, Nowell P. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somatic Cell and Molecular Genetics. 11: 297-302. PMID 2988138 DOI: 10.1007/Bf01534687 |
0.511 |
|
| 1985 |
Blaszczyk M, Pak KY, Herlyn M, Sears HF, Steplewski Z. Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America. 82: 3552-6. PMID 2582419 DOI: 10.1073/Pnas.82.11.3552 |
0.395 |
|
| 1985 |
Herlyn M, Balaban G, Bennicelli J, Guerry D, Halaban R, Herlyn D, Elder DE, Maul GG, Steplewski Z, Nowell PC, Clark WH, Koprowski H. Primary Melanoma Cells of the Vertical Growth Phase: Similarities to Metastatic Cells Journal of the National Cancer Institute. 74: 283-289. DOI: 10.1093/Jnci/74.2.283 |
0.569 |
|
| 1984 |
Herlyn M, Steplewski Z, Atkinson BF, Ernst CS, Koprowski H. Comparative study of the binding characteristics of monoclonal antimelanoma antibodies. Hybridoma. 1: 403-11. PMID 6765323 DOI: 10.1089/Hyb.1.1982.1.403 |
0.497 |
|
| 1984 |
Herlyn M, Steplewski Z, Herlyn D, Clark WH, Ross AH, Blaszczyk M, Pak KY, Koprowski H. Production and characterization of monoclonal antibodies against human malignant melanoma. Cancer Investigation. 1: 215-24. PMID 6667406 DOI: 10.3109/07357908309041361 |
0.507 |
|
| 1984 |
Balaban G, Herlyn M, Guerry D, Bartolo R, Koprowski H, Clark WH, Nowell PC. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genetics and Cytogenetics. 11: 429-39. PMID 6584203 DOI: 10.1016/0165-4608(84)90024-4 |
0.504 |
|
| 1984 |
Herlyn M, Sears HF, Verrill H, Koprowski H. Increased sensitivity in detecting tumor-associated antigens in sera of patients with colorectal carcinoma Journal of Immunological Methods. 75: 15-21. PMID 6512262 DOI: 10.1016/0022-1759(84)90220-5 |
0.487 |
|
| 1984 |
Herlyn D, Herlyn M, Ross AH, Ernst C, Atkinson B, Koprowski H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies Journal of Immunological Methods. 73: 157-167. PMID 6491298 DOI: 10.1016/0022-1759(84)90041-3 |
0.561 |
|
| 1984 |
Pak KY, Blaszczyk M, Herlyn M, Steplewski Z, Koprowski H. Identification and isolation of Lewis blood group antigens from human saliva using monoclonal antibodies. Hybridoma. 3: 1-10. PMID 6469267 DOI: 10.1089/Hyb.1984.3.1 |
0.466 |
|
| 1984 |
Blaszczyk M, Hansson GC, Karlsson KA, Larson G, Stromberg N, Thurin J, Herlyn M, Steplewski Z, Koprowski H. Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies. Archives of Biochemistry and Biophysics. 233: 161-8. PMID 6465894 DOI: 10.1016/0003-9861(84)90612-X |
0.457 |
|
| 1984 |
Herlyn M, Lange B, Bennicelli J, Blaszczyk M, Guerry D, Koprowski H. Increased levels of circulating HLA-DR antigen in sera of patients with acute lymphoblastoid leukemia. Leukemia Research. 8: 323-34. PMID 6431198 DOI: 10.1016/0145-2126(84)90071-7 |
0.491 |
|
| 1984 |
Herlyn M, Blaszczyk M, Sears HF, Verrill H, Lindgren J, Colcher D, Steplewski Z, Schlom J, Koprowski H. Detection of carcinoembryonic antigen and related antigens in sera of patients with gastrointestinal tumors using monoclonal antibodies in double-determinant radioimmunoassays. Hybridoma. 2: 329-39. PMID 6205981 DOI: 10.1089/Hyb.1983.2.329 |
0.48 |
|
| 1983 |
Ross AH, Cossu G, Herlyn M, Bell JR, Steplewski Z, Koprowski H. Isolation and chemical characterization of a melanoma-associated proteoglycan antigen Archives of Biochemistry and Biophysics. 225: 370-383. PMID 6614928 DOI: 10.1016/0003-9861(83)90042-5 |
0.484 |
|
| 1983 |
Zehngebot LM, Alexander MA, Guerry IV D, Cines DB, Mitchell K, Herlyn M. Functional consequence of variation in melanoma antigen expression Cancer Immunology Immunotherapy. 16: 30-34. PMID 6605801 DOI: 10.1007/Bf00199902 |
0.385 |
|
| 1983 |
Folberg R, Donoso LA, Herlyn MF, Koprowski H. Antigens in ocular and cutaneous melanomas. American Journal of Ophthalmology. 96: 394-5. PMID 6351625 DOI: 10.1016/S0002-9394(14)77837-7 |
0.426 |
|
| 1983 |
Steplewski Z, Herlyn M, Blaszczyk M, Koprowski H. A simple procedure for determining Lewis phenotypes in human saliva Journal of Immunological Methods. 62: 73-78. PMID 6348171 DOI: 10.1016/0022-1759(83)90112-6 |
0.446 |
|
| 1982 |
Brockhaus M, Magnani JL, Herlyn M, Blaszczyk M, Steplewski Z, Koprowski H, Ginsburg V. Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III are obtained from mice immunized with human tumors Archives of Biochemistry and Biophysics. 217: 647-651. PMID 7138030 DOI: 10.1016/0003-9861(82)90546-X |
0.477 |
|
| 1982 |
Sears HF, Herlyn M, Del Villano B, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. Journal of Clinical Immunology. 2: 141-9. PMID 7068816 DOI: 10.1007/Bf00916898 |
0.489 |
|
| 1982 |
Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma Journal of Clinical Immunology. 2: 135-140. PMID 7068815 DOI: 10.1007/Bf00916897 |
0.495 |
|
| 1982 |
Sears HF, Herlyn D, Herlyn M, Steplewski Z, Grotzinger P, Koprowski H. Ex vivo perfusion of human colon with monoclonal anticolorectal cancer antibodies Cancer. 49: 1231-1235. PMID 7059945 DOI: 10.1002/1097-0142(19820315)49:6<1231::AID-CNCR2820490626>3.0.CO;2-A |
0.446 |
|
| 1982 |
Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H. Expression of DR antigens in freshly frozen human tumors. Hybridoma. 1: 161-8. PMID 6208123 DOI: 10.1089/Hyb.1.1982.1.161 |
0.491 |
|
| 1981 |
Sears HF, Herlyn D, Herlyn M, Grotzinger PJ, Steplewski Z, Gerhard W, Koprowski H. Ex vivo perfusion of a tumor-containing colon with monoclonal antibody. The Journal of Surgical Research. 31: 145-50. PMID 6790874 DOI: 10.1016/0022-4804(81)90042-1 |
0.435 |
|
| 1981 |
Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma Science. 212: 53-55. PMID 6163212 DOI: 10.1126/Science.6163212 |
0.467 |
|
| 1979 |
Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma European Journal of Immunology. 9: 657-659. PMID 499332 DOI: 10.1002/Eji.1830090817 |
0.544 |
|
| 1979 |
Steplewski Z, Herlyn M, Herlyn D, Clark WH, Koprowski H. Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma European Journal of Immunology. 9: 94-96. PMID 374094 DOI: 10.1002/eji.1830090120 |
0.515 |
|
| 1979 |
Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies Proceedings of the National Academy of Sciences of the United States of America. 76: 1438-1442. PMID 286328 DOI: 10.1073/Pnas.76.3.1438 |
0.517 |
|
| 1979 |
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genetics. 5: 957-971. PMID 94699 DOI: 10.1007/Bf01542654 |
0.498 |
|
| 1978 |
Koprowski H, Steplewski Z, Herlyn D, Herlyn M. Study of antibodies against human melanoma produced by somatic cell hybrids Proceedings of the National Academy of Sciences of the United States of America. 75: 3405-3409. PMID 80012 DOI: 10.1073/Pnas.75.7.3405 |
0.555 |
|
| Show low-probability matches. |
